

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses

Protocol CR-6576 [REDACTED]

Version: 1.0

Date: 03 October 2024

Test Articles:

Marketed ACUVUE® OASYS 1-Day for Astigmatism contact lenses (Test Lens) from JJVCI and Dailies® Total1 for Astigmatism contact lenses (Control Lens) from Alcon Inc.

Commercially Available Product Lots: ACUVUE® OASYS 1-Day for Astigmatism contact lenses from JJVCI and Dailies® Total1 for Astigmatism contact lenses from Alcon Inc.

Keywords: Astigmatism, senofilcon A, ACUVUE® OASYS 1-Day for Astigmatism, Dailies® Total1 for Astigmatism contact lenses from Alcon, delefilcon A, daily wear, daily disposable, non-dispensing, Visual Analogue Scores, logMAR visual acuity, rotation performance.

Statement of Compliance to protocol, GCP and applicable regulatory guidelines:

This clinical trial will be conducted in compliance with ISO 14155:2020¹, Declaration of Helsinki², United States (US) Code of Federal Regulations (CFR)³, and International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP)⁴.

Confidentiality Statement:

This document contains confidential information, which should not be copied, referred to, released or published without written approval from Johnson & Johnson Vision Care, Inc. The information may not be disclosed to others except to the extent necessary to obtain Institutional Review Board/Independent Ethics Committee approval and informed consent, or as required by International, Federal and State Laws, as applicable. Persons to whom this information is disclosed must be informed that this information is privileged and confidential and that it should not be further disclosed without the written permission of Johnson & Johnson Vision Care, Inc. Any supplemental information that may be added to this document is also confidential and proprietary to Johnson & Johnson Vision Care, Inc. and must be kept in confidence in the same manner as the contents of this document.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

TABLE OF CONTENTS

PROTOCOL TITLE, NUMBER, VERSION AND DATE.....	6
SPONSOR NAME AND ADDRESS.....	6
MEDICAL MONITOR	6
AUTHORIZED SIGNATURES.....	7
CHANGE HISTORY	8
SYNOPSIS	9
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS	14
1. INTRODUCTION AND BACKGROUND.....	15
1.1. Name and Descriptions of Investigational Products	15
1.2. Intended Use of Investigational Products.....	15
1.3. Summary of Findings from Preclinical Studies	15
1.4. Summary of Known Risks and Benefits to Human Subjects	15
1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical Study	15
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES.....	15
2.1. Objectives	15
2.2. Endpoints	15
2.2.1. Efficacy Endpoints	15
2.2.2. Safety Endpoints.....	16
2.3. Hypotheses.....	17
3. TARGETED STUDY POPULATION	17
3.1. General Characteristics	17
3.2. Inclusion Criteria	17
3.3. Exclusion Criteria	17
3.4. Enrollment Strategy	18
4. STUDY DESIGN AND RATIONALE	18
4.1. Description of Study Design.....	18
4.2. Study Design Rationale.....	18
4.3. Enrollment Target and Study Duration	19
5. TEST ARTICLE ALLOCATION AND MASKING	19
5.1. Test Article Allocation.....	19
5.2. Masking	19
5.3. Procedures for Maintaining and Breaking the Masking.....	19
6. STUDY INTERVENTION	20
6.1. Identity of Test Articles	20
6.2. Ancillary Supplies/Products.....	20
6.3. Administration of Test Articles.....	20

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

6.4.	Packaging and Labeling.....	21
6.5.	Storage Conditions.....	21
6.6.	Collection and Storage of Samples	21
6.7.	Accountability of Test Articles	21
7.	STUDY EVALUATIONS	21
7.1.	Time and Event Schedule	21
7.2.	Detailed Study Procedures	22
	VISIT 1	22
	VISIT 2	26
	FINAL EVALUATION	29
7.3.	Unscheduled Visits	30
7.4.	Laboratory Procedures	31
8.	SUBJECTS COMPLETION/WITHDRAWAL	31
8.1.	Completion Criteria	31
8.2.	Withdrawal/Discontinuation from the Study	31
9.	PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION	32
9.1.	Systemic Medications	32
10.	DEVIATIONS FROM THE PROTOCOL.....	33
11.	STUDY TERMINATION	33
12.	PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS	34
13.	ADVERSE EVENTS	35
13.1.	Definitions and Classifications	35
13.2.	Assessing Adverse Events	37
	Causality Assessment.....	37
	Severity Assessment	37
13.3.	Documentation and Follow-Up of Adverse Events	38
13.4.	Reporting Adverse Events	39
	Reporting Adverse Events to Sponsor	39
	Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities	39
13.5.	Event of Special Interest.....	40
13.6.	Reporting of Pregnancy	40
14.	STATISTICAL METHODS	40
14.1.	General Considerations.....	40
14.2.	Sample Size Justification.....	40
14.3.	Analysis Populations	40
14.4.	Level of Statistical Significance	40
14.5.	Statistical Analyses.....	41
14.6.	Efficacy Analyses	41
	Primary Efficacy Endpoint.....	41

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Secondary Efficacy Endpoint.....	41
Other Efficacy Endpoints.....	41
14.7. Safety Analyses	42
Primary Safety Endpoint.....	42
Secondary Safety Endpoint.....	42
Other Safety Endpoints	42
14.8. Interim Analyses.....	42
14.9. Procedure for Reporting Deviations from Statistical Plan.....	42
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING.....	43
15.1. Electronic Case Report Form/Data Collection	43
15.2. Subject Record.....	43
15.3. Trial Registration on ClinicalTrials.gov	44
16. DATA MANAGEMENT	44
16.1. Access to Source Data/Document.....	44
16.2. Confidentiality of Information.....	44
16.3. Data Quality Assurance	44
16.4. Data Monitoring Committee (DMC)	44
17. CLINICAL MONITORING.....	44
18. ETHICAL AND REGULATORY ASPECTS	45
18.1. Study-Specific Design Considerations	45
18.2. Investigator Responsibility	45
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB).....	45
18.4. Informed Consent	46
18.5. Privacy of Personal Data	46
19. STUDY RECORD RETENTION	47
20. FINANCIAL CONSIDERATIONS.....	48
21. PUBLICATION	48
22. REFERENCES.....	48
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)	49
APPENDIX B: PATIENT INSTRUCTION GUIDE	53
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT).....	54
APPENDIX D: [REDACTED]	59
[REDACTED] LENS FITTING CHARACTERISTICS.....	60
[REDACTED] DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS.....	66
[REDACTED] TORIC FIT EVALUATION.....	72
[REDACTED] PATIENT REPORTED OUTCOMES	77
APPENDIX E: [REDACTED]	79
APPENDIX F: [REDACTED]	91

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX G: WORKAID FOR AUTOMATED TRACKING OF THE LENS ORIENTATION MARKER ON SOFT TORIC CONTACT LENSES	96
APPENDIX H: [REDACTED] GUIDELINES FOR COVID-19 RISK MITIGATION	101
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE	112

LIST OF TABLES

Table 1: Test Articles	20
Table 2: Ancillary Supplies	20
Table 3: Time and Events	21
Table 4: Disallowed systemic medications	32
Table 5: Disallowed systemic antihistamines	33
Table 6: Examples of major and minor protocol deviations	33

LIST OF FIGURES

Figure 1: Study Flowchart	13
---------------------------------	----

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

PROTOCOL TITLE, NUMBER, VERSION AND DATE

Title: Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses
Protocol Number: CR-6576
Version: 1.0
Date: 03 October 2024

SPONSOR NAME AND ADDRESS

Johnson & Johnson Vision Care, Inc. (JJVC)
7500 Centurion Parkway
Jacksonville, FL 32256

MEDICAL MONITOR



The Medical Monitor must be notified by the clinical institution/site by e-mail or telephone within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be contacted during business hours for adverse event questions. General study related questions should be directed towards the assigned clinical research associate.

The Medical Monitoring Plan is maintained as a separate document and included in the Trial Master File.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

AUTHORIZED SIGNATURES

The signatures below constitute the approval of this protocol and the attachments and provide the necessary assurances that this trial will be conducted according to all stipulations of the protocol, including all statements regarding confidentiality, and according to local legal and regulatory requirements, ISO 14155:2020,¹ Declaration of Helsinki², and the United States (US) Code of Federal Regulations (CFR)³, and International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP)⁴

Author & Study Responsible Clinician	<i>See Electronic Signature Report</i> [Redacted Signature]	_____ DATE
Clinical Operations Manager	<i>See Electronic Signature Report</i> [Redacted Signature]	_____ DATE
Co-Author	[Redacted Signature]	_____ DATE
Biostatistician	<i>See Electronic Signature Report</i> [Redacted Signature]	_____ DATE
Data Management	<i>See Electronic Signature Report</i> [Redacted Signature]	_____ DATE
Medical Safety Officer	<i>See Electronic Signature Report</i> [Redacted Signature]	_____ DATE
Medical Monitor	<i>See Electronic Signature Report</i> [Redacted Signature]	_____ DATE
Platform Lead/Project Lead/Director	<i>See Electronic Signature Report</i> [Redacted Signature]	_____ DATE

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

CHANGE HISTORY

Version	Originator	Description of Change(s) and Section Number(s) Affected	Justification for Change	Date
1.0	[REDACTED]	Original Protocol	Not Applicable	03 October 2024

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

SYNOPSIS

Protocol Title	Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses
Sponsor	JJVC, 7500 Centurion Parkway, Jacksonville, FL 32256
Clinical Phase	Clinical trial phase: Feasibility Design control phase: Development phase, phase 0.
Trial Registration	This study will be registered on ClinicalTrials.gov by the sponsor.
Test Article(s)	Investigational Products: None Approved Products (locally sourced by research site): 1. ACUVUE® OASYS 1-Day for Astigmatism (AO1DfA) contact lenses for Johnson and Johnson Vision Inc. (Test Lens) 2. Dailies® Total1 for Astigmatism (DT1fA) contact lenses from Alcon Inc. (Control Lens)
Wear and Replacement Schedules	Wear Schedule: daily wear Replacement Schedule: daily disposable
Objectives	Primary Objective: The primary objective of this study is to measure the monocular distance (6m) logMAR visual acuity with each study lens (Test lens and Control lens) after lens fitting. Other (Exploratory) Objectives: The exploratory objectives of this study include changes in lens orientation after settling and over time with an automated lens tracking system; VAS scores after lens fitting for vision, comfort and handling; and lens orientation at 1, 3, and 15-minutes following insertion. Adverse events and slit lamp findings will also be monitored and collected.
Study Endpoints	Primary Efficacy Endpoint: 1. Distance Visual Acuity Other (Exploratory) Efficacy Endpoints: 1. Lens orientation measured over time with an automated lens tracking system following intentional misalignment 2. Lens orientation recorded with an automated lens tracking system following eye movements 3. Settling Time following intentional misalignment 4. Toric Lens orientation at 1-, 3-, and 15-minutes following insertion 5. Subjective Vision, Comfort and Handling Scores approximately 15-minutes after lens insertion Other Safety Endpoints: 1. Adverse Events (AEs) 2. Slit Lamp Findings (SLFs)

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Study Design	This will be a single site, 2-visit, randomized, controlled, single-masked, non-dispensing, bilateral wear, 2×2 cross-over study. Each subject will be randomly assigned to one of two wear sequences. There will be a washout period of 1-10 days in between the visits. There will be a total of 2 visits: Visit 1: Screening, baseline evaluation and lens fit #1 Visit 2: Continuance, lens fit #2, Exit evaluation See the flow chart at the end of the synopsis table for the schematic of the study visits and procedures of main observations ().
Sample Size	This study will have an enrollment target of approximately 7 subjects, with a target of at least 5 to complete. This is a crossover study, and all subjects will be randomized to one of 2 unique sequences of lens wear.
Study Duration	Total study duration including the enrollment period is anticipated to be approximately 6 weeks. The expected duration of participation of the subject will be approximately 1 week.
Anticipated Study Population	Subjects will be habitual toric, soft contact lens wearers with bilateral astigmatism who are between 18 and 39 years of age (inclusive).
Eligibility Criteria - Inclusion	Potential subjects must satisfy of all the following criteria to be enrolled in the study. Inclusion Criteria following Screening The subject must: 1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form. 2. Appear able and willing to adhere to the instructions set forth in this clinical protocol. 3. Be between 18 and 39 years of age (inclusive) at the time of screening. 4. Habitually wear soft, toric contact lenses in both eyes in a daily or daily disposable wear modality (i.e. not extended wear modality). Habitual wearer is defined as a minimum of 6 hours per day, for a minimum of 2 days per week during the past 30 days. 5. Possess a wearable pair of spectacles that provide correction for distance vision (if applicable). Inclusion Criteria at Baseline Evaluation The subject must: 6. Have the spherical component of their vertex-corrected distance refraction within the range +4.00 to -6.00 DS (inclusive) in both eyes. 7. Have the magnitude of the negative cylindrical component of their vertex-corrected distance refraction between 0.75 DC and 2.50 DC in both eyes. 8. Have best corrected monocular distance logMAR visual acuity of 0.2 or better in each eye.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.


Eligibility Criteria – Exclusion	Potential subjects who meet any of the following criteria will be excluded from participating in the study. Exclusion Criteria following Screening The subject must not: 1. Be currently pregnant or lactating. 2. Be diabetic. 3. Be currently using any ocular medications or have any ocular infection of any type. 4. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications. 5. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months. 6. Be currently wearing monovision or multifocal contact lenses. 7. Be currently wearing lenses in an extended wear modality. 8. Be currently wearing or have had worn Acuvue® Oasys 1-Day for Astigmatism, or Dailies® Total1 for Astigmatism lenses during the last 3 months. 9. Have a history of strabismus or amblyopia. 10. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site. 11. Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment. Exclusion Criteria at Baseline Evaluation The subject must not: 12. Have clinically significant (grade 3 or higher on the Efron grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis). 13. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions. 14. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
Disallowed Medications/Interventions	Subjects will not be eligible to enroll if they are taking any ocular medications, or any systemic medications that would normally contraindicate contact lens wear or may otherwise compromise study endpoints. See section 9.1 for details regarding disallowed systemic medications.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Measurements and Procedures	The key procedure associated with the primary endpoint for this study will be the evaluation of monocular logMAR visual acuity. Other measurements and procedures related to observational endpoints will include: - Lens orientation and stability in different time points following insertion - Lens rotation over time following intentional misalignment measured with an automated lens tracking instrument - Lens orientation following eye movements in 8 directions of gaze - Completion of the VAS questionnaires at fitting
Microbiology or Other Laboratory Testing	Not applicable for this study.
Study Termination	The occurrence of an Unanticipated Adverse Device Effect (UADE), Unanticipated Serious Adverse Device Effect (USADE), or Serious Adverse Event (SAE) for which a causal relationship to a test article cannot be ruled out, may result in stopping further dispensing of the test article. In the event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the Principal Investigator before any further subjects are enrolled.
Ancillary Supplies/ Study-Specific Materials	Non-preserved saline (locally sourced by research site)
Principal Investigator(s) and Study Institution(s)/Site(s)	A full list of Principal Investigators, clinical sites, and institutions is kept separately from the Study Protocol and is included in the study Trial Master File.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Figure 1: Study Flowchart



Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS

ADE	Adverse Device Effect
ADHD	Attention Deficit Hyperactivity Disorder
AE	Adverse Event/Adverse Experience
AO1DfA	ACUVUE OASYS® 1-DAY with HydraLuxe™ TECHNOLOGY for
	ASTIGMATISM
BSCVA	Best Spectacle Corrected Visual Acuity
CFR	Code of Federal Regulations
CI	Confidence Interval
CLUE	Contact Lens User Experience
COM	Clinical Operations Manager
CRA	Clinical Research Associate
CRF	Case Report Form
CRO	Contract Research Organization
D	Diopter
DMC	Data Monitoring Committee
DT1fA	Dailies® Total1 for Astigmatism
eCRF	Electronic Case Report Form
EDC	Electronic Data Capture
ESD	Eyelid Stabilized Design
ETDRS	Early Treatment Diabetic Retinopathy Study
FDA	Food and Drug Administration
GCP	Good Clinical Practice
HEV	High Energy Visible
HIPAA	Health Insurance Portability and Accountability Act
HIV	Human Immunodeficiency Virus
HLHC	High-Luminance, High-Contrast
IB	Investigator's Brochure
ICH	The International Council for Harmonization
IDE	Investigational Device Exemption
IEC	Independent Ethics Committee
IRB	Institutional Review Board
ISO	International Organization for Standardization
ITT	Intention-to-Treat
JJVC	Johnson & Johnson Vision Care, Inc.
LASIK	Laser-Assisted in Situ Keratomileusis
LogMAR	Logarithm of Minimal Angle of Resolution
OD	Right Eye
OS	Left Eye
OU	Both Eyes
PIG	Patient Instruction Guide
PQC	Product Quality Complaint
PRK	Photorefractive Keratectomy
PRO	Patient Reported Outcome
QA	Quality Assurance
SAE	Serious Adverse Event/Serious Adverse Experience
SAP	Statistical Analysis Plan
SAS	Statistical Analysis System
SD	Standard Deviation
SLF	Slit Lamp Findings
UADE	Unanticipated Adverse Device Effect
USADE	Unanticipated Serious Adverse Device Effect
UV	Ultraviolet
VA	Visual Acuity
VAS	Visual Analogue Scale

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

1. INTRODUCTION AND BACKGROUND

Johnson and Johnson Vision currently market ACUVUE® OASYS 1-Day for Astigmatism daily disposable contact lenses which uses Blink Stabilized Technology to achieve rotational stability, while other manufacturers use other prism or peri-ballast mechanisms for rotational stability.

This study is designed to assess monocular distance visual acuity with the two marketed study lenses. The study will also evaluate the rotational performance of the two marketed lenses using an automated lens tracking instrument and custom software developed by Eurolens Research, at the University of Manchester.

1.1. Name and Descriptions of Investigational Products

No investigational test lenses will be used in the study. Both test articles used in the study are marketed products: ACUVUE® OASYS 1-Day for Astigmatism contact lenses from JJVCI and Dailies® Total1 for Astigmatism contact lenses from Alcon Inc.

Further details about the test articles can be found in section 6 of this protocol.

1.2. Intended Use of Investigational Products

The products tested in the study are marketed products and are not investigational.

1.3. Summary of Findings from Preclinical Studies

Not applicable.

1.4. Summary of Known Risks and Benefits to Human Subjects

The anticipated clinical benefit of the marketed lenses will be the correction of refractive error in subjects with astigmatic component.

Comprehensive risk and benefit information regarding the marketed lenses is included in the package insert of the marketed products (Appendix C)

1.5. Relevant Literature References and Prior Clinical Data Relevant to Proposed Clinical Study

For further details regarding references and prior data relevant to the marketed lenses, refer to the Appendix C.

2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES

2.1. Objectives

Primary Objective

The primary objective of this study is to measure the monocular distance (6m) logMAR visual acuity with each study lens (Test lens and Control lens) after lens fitting.

Other (Exploratory) Objectives

The exploratory objectives of this study include lens orientation and stability after settling, changes in lens orientation over time following intentional misalignment, changes in lens orientation following eye movements in 8 directions of gaze, VAS scores at fitting (comfort, vision, and handling), and lens orientation at 1- and 3-minutes following insertion. Adverse events will also be monitored and collected.

2.2. Endpoints

2.2.1. Efficacy Endpoints

Primary Efficacy Endpoint

1. Distance (6m) Visual Acuity

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

The primary endpoint for this study will be distance visual acuity measured monocularly at 6 meters after lens fitting under high-luminance high contrast (HLHC) lighting conditions using the EuroLens computerized logMAR VA chart. The logMAR VA score is a continuous endpoint.

Other (Exploratory) Efficacy Endpoints

1. Lens orientation measured over time with an automated lens tracking system following intentional misalignment

Each study lens will be rotated in the temporal direction from its original position to its worst case orientation (90° from its settled position for the AO1DfA lens which has a bidirectional stabilization design, and 180° from its settled position for the DT1fA lens which has a unidirectional stabilization design), followed by video capture of the lens orientation over a 5-minute period. Lens orientation data (rotation error magnitude and direction relative to the 6 o'clock position, and rotation error magnitude and direction relative to original settled position) will be calculated at 5-second increments through the measurement period. Rotation error magnitude will be recorded in degrees (0 to 180), and rotation error direction will be recorded as base temporal or nasal. For the DT1fA lens type, recovery from 90° misalignment will also be determined from the timepoint that it reaches this position during the recovery from 180° of misalignment.

2. Lens orientation recorded with an automated lens tracking system following eye movements

Lens settled orientation (rotation error magnitude and direction relative to the 6 o'clock position) in primary gaze will be measured. Lens orientation will then be measured again after the subject has been asked to perform an eye movement in each of the eight cardinal directions of gaze. The difference in orientation (magnitude and direction) from before eye movement to after eye movement will be determined.

3. Settling Time following intentional misalignment

The time (in seconds) required for the study lenses to settle (defined as returning to within 5 degrees of initial settled position) after intentional misalignment will be recorded for each eye and lens during the assessment of the lens orientation recorded with an automated lens tracking system (Other efficacy endpoint 1). Settling time is a continuous endpoint.

4. Toric lens orientation

Toric lens orientation (scribe mark position relative to 6 o'clock) will be assessed for each eye at 1, 3 and at least 15 minutes after lens insertion at the fitting visit. The endpoint is the distribution (counts, percentages) of eyes for the toric orientation (in degrees). Toric lens stability with blink at least 15 minutes after lens insertion will also be recorded. See [REDACTED] in Appendix D for details regarding the collection of lens orientation.

5. Subjective Vision, Comfort and Handling Scores

Vision, comfort and handling will be assessed monocularly approximately 15-minutes after lens insertion using individual questionnaire items with a Visual Analogue Scale (VAS). The VAS scale for each item is continuous set where scores range from 0 (represent worst imaginable vision, comfort, or extreme difficulty in lens handling) to 100 (represent best imaginable vision, comfort, or easiest to handle). Vision, comfort, and handling scores are continuous endpoints. See appendix A for the details of the study questionnaire.

2.2.2. Safety Endpoints

Primary Safety Endpoint

Not applicable

Secondary Safety Endpoint

Not applicable

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Other Safety Endpoint

1. Adverse events (AEs) - including ocular and non-ocular. Details for AEs will be provided through listings.
2. Slit lamp findings (SLFs) – the SLF grades determined using the Efron Grading Scale will be summarized descriptively.

2.3. Hypotheses

Not applicable, no statistical hypothesis testing will be performed for any endpoints in this study.

3. TARGETED STUDY POPULATION

3.1. General Characteristics

The target population for this study will be healthy adult soft, toric contact lens wearers between 18 and 39 years of age with binocular astigmatism.

3.2. Inclusion Criteria

Potential subjects must satisfy all of the following criteria to be enrolled in the study:

Inclusion Criteria following Screening

The subject must:

1. Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
2. Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3. Be between 18 and 39 years of age (inclusive) at the time of screening.
4. Habitually wear soft, toric contact lenses in both eyes in a daily or daily disposable wear modality (i.e. not extended wear modality). Habitual wearer is defined as a minimum of 6 hours per day, for a minimum of 2 days per week during the past 30 days.
5. Possess a wearable pair of spectacles that provide correction for distance vision (if applicable).

Inclusion Criteria at Baseline Evaluation

The subject must:

6. Have the spherical component of their vertex-corrected distance refraction within the range +4.00 to -6.00 DS (inclusive) in both eyes.
7. Have the magnitude of the cylindrical component of their vertex-corrected distance refraction between 0.75 DC and 2.50 DC in both eyes.
8. Have best corrected monocular distance visual acuity of 0.2 or better in each eye.

3.3. Exclusion Criteria

Potential subjects who meet any of the following criteria will be excluded from participating in the study:

Exclusion Criteria following Screening

The subject must not:

1. Be currently pregnant or lactating.
2. Be diabetic.
3. Be currently using any ocular medications or have any ocular infection of any type.
4. By self-report, have any ocular or systemic disease, allergies, infection, or use of medication that might contraindicate or interfere with contact lens wear, or otherwise compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculosis), contagious immunosuppressive disease

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

- (e.g., Human Immunodeficiency Virus [HIV]), autoimmune disease (e.g. rheumatoid arthritis, Sjögren's syndrome), or history of serious mental illness or seizures. See section 9.1 for additional details regarding excluded systemic medications.
5. Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or hybrid lenses (e.g. SynergEyes, SoftPerm) within the past 6 months.
 6. Be currently wearing monovision or multifocal contact lenses.
 7. Be currently wearing lenses in an extended wear modality.
 8. Be currently wearing or have had worn Acuvue® Oasys 1-Day for Astigmatism, or Dailies® Total1 for Astigmatism lenses during the last 3 months.
 9. Have a history of strabismus or amblyopia.
 10. Be an employee (e.g., Investigator, Coordinator, Technician) or immediate family member of an employee (including partner, child, parent, grandparent, grandchild or sibling of the employee or their spouse) of the clinical site.
 11. Have participated in a contact lens or lens care product clinical trial within 7 days prior to study enrollment.

Exclusion Criteria at Baseline Evaluation

The subject must not:

12. Have clinically significant (grade 3 or higher on the Efron grading scale) slit lamp findings (e.g., corneal edema, neovascularization or staining, tarsal abnormalities or bulbar injection) or other corneal or ocular disease or abnormalities that contraindicate contact lens wear or may otherwise compromise study endpoints (including entropion, ectropion, chalazia, recurrent styes, glaucoma, history of recurrent corneal erosions, aphakia, moderate or above corneal distortion, herpetic keratitis).
13. Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
14. Have had or have planned (within the study period) any ocular or intraocular surgery (e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).

3.4. Enrollment Strategy

Study subjects will be recruited from the Institution/clinical site's subject database and/or utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved materials.

4. STUDY DESIGN AND RATIONALE

4.1. Description of Study Design

This will be a single site, 2-visit, randomized, controlled, single-masked, non-dispensing, bilateral wear, 2×2 cross-over study. Each subject will be randomly assigned to one of two wear sequences (AO1DfA followed by DT1fA or DT1fA followed by AO1DfA), with a 1-to-10 day(s) washout period between wear periods. Lens rotation will be assessed over time with a slit lamp as well as with an automated lens tracking software. Subjective comfort, vision and handling will be assessed using the VAS questionnaire at fitting for each wear period. High Luminance High Contrast LogMAR VA will be assessed. Subjects will not have access to the study lenses following completion of the protocol.

4.2. Study Design Rationale

A 2-Visit single-masked, non-dispensing 2×2 crossover was chosen to evaluate the study objectives so that subjects can act as their own control. One study lens will be worn per visit, there will be a washout period of 1 to 10 days between study visits.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

4.3. Enrollment Target and Study Duration

This study will have an enrollment target of approximately 7 subjects, with a target of at least 5 to complete. The study will be conducted at 1 clinical site. A subject will be considered enrolled upon signing of the informed consent form.

There will be 2 visits in total per subject; total study duration including the enrollment period is expected to be approximately 6 weeks. Subjects who are discontinued prior to the final evaluation may be replaced at the discretion of the study sponsor. The investigation will end at the time when all visits have been completed for all enrolled subjects and the study data is locked.

5. TEST ARTICLE ALLOCATION AND MASKING

5.1. Test Article Allocation

The study lenses will be worn bilaterally in a randomized fashion using a 2×2 crossover design.

A computer-generated randomization scheme will be used to randomly assign subjects to one of two unique sequences of lens wear (AO1DfA/DT1fA or DT1fA/AO1DfA) using an allocation ratio of 1:1 between lens sequences. The randomization scheme will be generated using the PROC PLAN procedure from SAS Software Version 9.4 or higher (SAS Institute, Cary, NC)⁵.

The randomized assignment of subjects will be performed at the first visit prior to the first fitting. The Clinical site will follow the randomization scheme provided and will not pre-select or assign subjects. The following must have occurred prior to randomization:

- Informed consent must have been obtained
- The subject must have met all inclusion and exclusion criteria
- The subject history and baseline information must have been collected

When dispensing test articles, the following steps should be followed to maintain randomization codes:

1. Investigator or designee (documented on the Delegation Log) will consult the randomization scheme (lens fitting schedule) to obtain the test article assignment for that subject prior to dispensing.
2. Investigator or designee will record the subject's number on the appropriate line of the randomization scheme (lens fitting schedule).
3. Investigator or designee will pull the appropriate test articles from the study supply. All test articles that are opened, whether dispensed (placed/fit on eye or dispensed outside the clinical site) or not, must be recorded on the Test Article Accountability Log in the "Dispensed" section.

5.2. Masking

This is a single-masked trial. Subjects will be masked to both study lenses. The study staff responsible for choosing the appropriate lens (site investigators or other site personnel) as per the randomization scheme will remove the foil from the packaging prior to providing lenses to subjects for lens insertion, so that the subjects may remain masked throughout the study.

Investigators and site personnel will not be masked to the study lenses due to the difference in packaging and lens markings.

5.3. Procedures for Maintaining and Breaking the Masking

Not applicable. As this is a non-dispensing trial, there is no foreseen situation in which the site would need to inform the subject of what contact lens they are wearing.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

6. STUDY INTERVENTION

6.1. Identity of Test Articles

The following contact lenses will be used in this study:

Table 1: Test Articles

	Acuvue® Oasys 1-Day for Astigmatism (Test)	Dailies® Total 1 for Astigmatism (Control)
Test Article Form	Soft toric contact lenses	
Description	Standard marketed lenses	
Manufacturer	Johnson & Johnson Vision Care, Inc.	Alcon Inc.
Packaging Form	Blister packaging with sterile packing solution	Blister packaging with sterile packing solution
Packaging Solution	Optimized Borate Buffer (OBB) solution	Packaged in solution containing wetting agents
Lens Material	senofilcon A	delefilcon A
Sphere Powers (DS)	Marketed SKUs (+4.00 to -6.00)	
Cylinder Powers (DC)	Marketed SKUs (0.75 to 2.50)	
Cylinder Axes (°)	Marketed SKUs	
Nominal Water Content (%)	41	Variable
Nominal Base Curve (mm)	8.5	8.6
Lens Diameter (mm)	14.3	14.5
Fiducial marks	6 and 12 o'clock fiducial lines	6 o'clock fiducial line
Dk	103	140
Wear Modality in Current Study	Daily wear	
Replacement Frequency in Current Study	Daily disposable	
Commercially available	Yes	Yes

The site will be acquiring and using the commercially available lots to match the prescription per subject.

6.2. Ancillary Supplies/Products

The following solutions will be used in this study:

Table 2: Ancillary Supplies

	Non-Preserved Saline
Solution Name/Description	Astroplast Ultra Saline 20ml Pods or similar
Manufacturer	Wallace Cameron International Ltd
Preservative	None

The sites will be acquiring the ancillary supplies as needed for the study including lens cases or fluorescein strips.

6.3. Administration of Test Articles

Test articles will be dispensed to subjects meeting all eligibility requirements, for in-office wear only as part of the requirements set forth in this clinical protocol.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

6.4. Packaging and Labeling

This will be an open-label, non-dispensing study. The lenses used in the study will be available in commercial primary and secondary packaging. Sample labels are not included in this section by the sponsor because the study lenses will be locally sourced by the research site.

6.5. Storage Conditions

Test articles will be maintained at ambient temperatures at the clinical site. Test articles must be kept under secure conditions.

6.6. Collection and Storage of Samples

All lenses worn will not be collected for return to JJVC. When possible, any lens or test article associated with an Adverse Events and/or a Product Quality Complaint must be retained and stored in a glass vial with moderate unpreserved saline solution pending directions from the sponsor for potential return back to JJVC.

6.7. Accountability of Test Articles

The principal investigator and the research site will procure sufficient quantities of study articles and supplies to complete the investigation.

The Investigator may delegate this activity to authorized study site personnel listed on the Site Delegation Log. This includes:

1. What was dispensed for the subject for trial fitting
2. The number and reason for unplanned replacements.

7. STUDY EVALUATIONS

7.1. Time and Event Schedule

Table 3: Time and Events

Visit Information	Visit 1 Screening, Baseline, Lens Fitting #1	Visit 2 Lens Fitting #2
Time Point	Day 0	1-10 Days after Visit 1
Estimated Visit Duration	1.5 hours	2.0 hours
Statement of informed consent	x	
Demographics	x	
Medical history/concomitant medications	x	x
Habitual contact lens information	x	
Eligibility at Screening	x	
Entrance visual acuity	x	x
Adverse event review (if applicable)		x
Keratometry	x	
Subjective sphero-cylindrical refraction	x	
Slit lamp biomicroscopy	x	x
Eligibility after baseline	x	
Randomization	x	

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit Information	Visit 1 Screening, Baseline, Lens Fitting #1	Visit 2 Lens Fitting #2
Time Point	Day 0	1-10 Days after Visit 1
Estimated Visit Duration	1.5 hours	2.0 hours
Lens selection	x	x
OD lens insertion	x	x
Lens rotation assessments (1-minute and 3-minutes post insertion)	x	x
OS lens insertion	x	x
Lens rotation assessments (1-minute and 3-minutes post insertion)	x	x
Lens rotation assessment after lens settling (at least 15 mins)	x	x
HLHC visual acuity	x	x
VAS Scores post fitting	x	x
Automated lens tracking per work-aid	x	x
Lens removal	x	x
Slit lamp biomicroscopy	x	
Exit Visual acuity	x	
Schedule another appointment	x	
Exit evaluation		x

7.2. Detailed Study Procedures

VISIT 1

Subjects must wear their spectacles to this visit (if applicable), without having worn their lenses the day of the visit.

Visit 1: Screening			
Step	Procedure	Details	Work aid
1.1	Statement of Informed Consent	Each subject must read, understand, and sign the Statement of Informed Consent before being enrolled into the study. The Principal Investigator or his/her designee conducting the informed consent discussion must also sign the consent form. Note: The subject must be provided a signed copy of this document.	
1.2	Demographics	Record the subject's year of birth, age, gender, race and ethnicity.	
1.3	Medical History and Concomitant Medications	Record the subject's medical history and concomitant medications.	
1.4	Habitual Lenses	Record the subject's habitual lens type, parameters, lens care solution, wear modality and approximate prescription date.	
1.5	Habitual Lens Wear Time	Record the subject's duration of lens wear in years and months, minimum days worn per week, and average daily wear time for their habitual lenses.	

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit 1: Screening			
Step	Procedure	Details	/ Work aid
1.6	Eligibility after Screening	All responses to Screening Inclusion Criteria questions must be answered “yes” and all responses to Exclusion Criteria must be answered “no” for the subject to be considered eligible. <i>If subject is deemed to be ineligible after screening, proceed to Final Evaluation and complete Subject Disposition. Refraction and Biomicroscopy forms do not need to be completed as part of Final Evaluation.</i>	

Visit 1: Baseline			
Step	Procedure	Details	/ Work aid
1.7	Entrance visual acuity	Record the monocular distance LogMAR visual acuity for each eye (OD, OS) with subject’s habitual spectacle refraction in place.	Appendix E: [REDACTED]
1.8	Keratometry	Record Keratometry values from both eyes in Radii (mm) and Axes.	
1.9	Subjective spherocylindrical refraction	Conduct a full spherocylindrical bare eye subjective refraction with binocular balance and record the resultant monocular visual acuity for each eye.	and Appendix E: [REDACTED]
1.10	Slit lamp biomicroscopy	Grades will be scored to the nearest 0.1 in the best judgment of the investigator using Efron Grading Scales. If any slit lamp findings are Efron Grade 3 or greater (e.g., corneal edema, corneal neovascularization, tarsal abnormalities, conjunctival injection) or Efron Grade <3 which in the investigator’s opinion would contraindicate contact lens wear, the subject may not continue. In such cases, complete subject disposition and exit evaluation.	Appendix F: [REDACTED]
1.11	Eligibility at baseline	All responses to Inclusion Criteria questions must be answered “yes” and all responses to Exclusion Criteria questions must be answered “no” for the subject to be considered eligible. If subject is deemed to be ineligible after baseline, proceed to Final Evaluation.	

Visit 1: Lens Fitting #1			
Step	Procedure	Details	/ Work aid
1.12	Randomization	Assign the randomization ID to the subject.	


Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit 1: Lens Fitting #1			
Step	Procedure	Details	/ Work aid
1.13	Lens selection	Assign the study lens based on the randomization scheme. Select the fitting lens powers based on vertex-corrected subjective refraction for each eye. Before presenting the lenses to the subject, completely remove the foil label to maintain subject masking.	
1.14	Right eye lens insertion	The subject will insert the right lens in a random orientation. If lens is uncomfortable, inspect for damage and remove, reinsert or replace as necessary. If the lens is associated with a Product Quality Complaint then, secure and retain the lens in a glass vial. Contact the sponsor for additional actions.	
1.15	Timed rotation assessments during settling period	Start a stopwatch (or suitable smartphone or tablet timing app) as soon as the right lens is inserted. Record lens orientation (direction and magnitude of rotation error) to the nearest degree at one (1) and three (3) minutes following insertion.	
1.16	Left eye lens insertion	The subject will insert the left lens with a random orientation. If lens is uncomfortable, inspect for damage and remove, reinsert or replace as necessary. If the lens is associated with a Product Quality Complaint, then secure and retain the lens in a glass vial. Contact the sponsor for additional actions.	
1.17	Timed rotation assessments during settling period	Start a stopwatch (or suitable smartphone or tablet timing app) as soon as the left lens is inserted. Record lens orientation (direction and magnitude of rotation error) to the nearest degree at one (1) and three (3) minutes following insertion.	
1.18	Lens settling	Allow lenses to settle for a period of at least 15 minutes following left lens insertion.	
1.19	Toric fit assessment	Record for each eye: 1. The lens orientation (direction and magnitude of rotation error) to the nearest degree 2. Lens stability with blinks 3. Toric fit acceptability. The toric lens fit will be designated as 'unacceptable' if either: a. The magnitude of lens rotation error is greater than 20 degrees b. The LENS STABILITY WITH BLINK is greater than 5 degrees If one or both lenses demonstrate an unacceptable toric fit, the subject will be discontinued (proceed to final evaluation).	

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit 1: Lens Fitting #1			
Step	Procedure	Details	/ Work aid
1.20	General lens fit assessment	The fitting characteristics of the lens in both eyes will be assessed using a slit lamp. Lens position (centration, limbal exposure, edge lift) and movement (primary and up gaze as well as push-up) will be assessed. Fit acceptability is defined as any lens that does not display the following general fit characteristics: • Limbal exposure (presence of clear cornea) in any direction of gaze. • Edge lift • Insufficient movement in all three movement assessments (primary gaze, up-gaze and push-up test). • Excessive movement in primary gaze If the general fit is unacceptable for either eye, the subject will be discontinued (proceed to exit evaluation).	
1.21	HLHC Visual acuity	Record monocular distance LogMAR Visual Acuity.	Appendix E: [REDACTED]
1.22	Continuance	The subject will continue further if they meet both criteria: • The settled lens rotation and stability are deemed acceptable for both eyes. • The monocular visual acuity with the study lenses is 0.2 LogMAR or better. If, for either eye, the above-mentioned criteria are not met, the subject will be discontinued (proceed to final evaluation).	
1.23	Post-fit VAS questionnaire	Subjects will complete a VAS questionnaire regarding the initial comfort, vision and handling of the study lenses.	[REDACTED]

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit 1: Lens Fitting #1			
Step	Procedure	Details	/ Work aid
1.24	Automated Lens tracking	Subjects will complete a session where the lens orientation will be tracked with an automated lens tracking system for a period of 5 minutes following intentional mis-rotation of the study lens from its settled position in the base temporal direction (by 90 degrees for AO1DfA, and by 180 degrees for DT1fA). The mis-rotation of the lens will be performed by the investigator using their finger while wearing suitable disposable medical examination gloves. The mis-rotation and subsequent lens tracking will be done for one eye at a time. Lens orientation will then be measured before and after a series of eye movements in the eight cardinal directions of gaze. <i>Note: Orientation data from the automated lens tracking system will not be entered into EDC, but will instead be provided as an external data set.</i>	Appendix G: Work Aid
1.25	Lens removal	The subject will remove both lenses. The worn lenses will be discarded unless it is associated with a Product Quality Complaint (PQC) or an Adverse event (AE).	
1.26	Slit lamp biomicroscopy	Grades will be scored to the nearest 0.1 in the best judgment of the investigator using Efron Grading Scales. If any slit lamp findings are Efron Grade 3 or greater (e.g., corneal edema, corneal neovascularization, tarsal abnormalities, conjunctival injection), record an Adverse event and subject will be discontinued from the study.	Appendix F: 
1.27	Exit visual acuity	Record the monocular distance LogMAR visual acuity for each eye (OD, OS) with subject's habitual spectacle refraction in place.	Appendix E: 
1.28	Schedule next visit	Schedule the follow-up visit to occur in 1-10 days (counting the day of this visit as day 0. Ensure the subject is instructed to present to the next visit with their spectacles, without having worn contact lenses, the day of the visit. The subject may wear their habitual contact lenses during the washout period.	

VISIT 2

Subjects must wear their spectacles to this visit (if applicable), without having worn their lenses the day of the visit.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit 2: Lens fitting #2			
Step	Procedure	Details	Work aid
2.1	Review medical history and concomitant medications	Record any changes to the subject's medical history (including adverse events) or concomitant medications.	
2.2	Entrance visual acuity	Record the monocular distance LogMAR visual acuity for each eye (OD, OS) with subject's habitual spectacle refraction in place.	Appendix E: [REDACTED]
2.3	Slit lamp biomicroscopy	Grades will be scored to the nearest 0.1 in the best judgment of the investigator using Efron Grading Scales. If any slit lamp findings are Efron Grade 3 or greater (e.g., corneal edema, corneal neovascularization, tarsal abnormalities, conjunctival injection), record an Adverse event and subject will be discontinued from the study.	Appendix F: [REDACTED]
2.4	Continuance	Indicate that the subject is eligible to continue participation in the study.	
2.5	Lens selection	Assign the study lens based on the randomization scheme. Select the fitting lens powers based on vertex-corrected subjective refraction for each eye. Before presenting the lenses to the subject, completely remove the foil label to maintain subject masking.	
2.6	Right eye lens insertion	The subject will insert the right lens in a random orientation. If lens is uncomfortable, inspect for damage and remove, reinsert or replace as necessary. If the lens is associated with a Product Quality Complaint then, secure and retain the lens in a glass vial. Contact the sponsor for additional actions.	
2.7	Timed rotation assessments during settling period	Start a stopwatch (or suitable smartphone or tablet timing app) as soon as the right lens is inserted. Record lens orientation (direction and magnitude of rotation error) to the nearest degree at one (1) and three (3) minutes following insertion.	[REDACTED]
2.8	Left eye lens insertion	The subject will insert the left lens in a random orientation. If lens is uncomfortable, inspect for damage and remove, reinsert or replace as necessary. If the lens is associated with a Product Quality Complaint then, secure and retain the lens in a glass vial. Contact the sponsor for additional actions.	
2.9	Timed rotation assessments during settling period	Start a stopwatch (or suitable smartphone or tablet timing app) as soon as the left lens is inserted. Record lens orientation (direction and magnitude of rotation error) to the nearest degree at one (1) and three (3) minutes following insertion.	[REDACTED]
2.10	Lens settling	Allow lenses to settle for a period of at least 15 minutes following left lens insertion.	

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit 2: Lens fitting #2			
Step	Procedure	Details	Work aid
2.11	Toric fit assessment	Record for each eye: 1. The lens orientation (direction and magnitude of rotation error) to the nearest degree 2. Lens stability with blinks 3. Toric fit acceptability. The toric lens fit will be designated as 'unacceptable' if either: c. The magnitude of lens rotation error is greater than 20 degrees d. The LENS STABILITY WITH BLINK is greater than 5 degrees If one or both lenses demonstrate an unacceptable toric fit, the subject will be discontinued (proceed to final evaluation).	
2.12	General lens fit assessment	The fitting characteristics of the lens in both eyes will be assessed using a slit lamp. Lens position (centration, limbal exposure, edge lift) and movement (primary and up gaze as well as push-up) will be assessed. Fit acceptability is defined as any lens that does not display the following general fit characteristics: • Limbal exposure (presence of clear cornea) in any direction of gaze. • Edge lift • Insufficient movement in all three movement assessments (primary gaze, up-gaze and push-up test). • Excessive movement in primary gaze If the general fit is unacceptable for either eye, the subject will be discontinued (proceed to exit evaluation).	
2.13	HLHC Visual acuity	Record monocular distance LogMAR Visual Acuity.	Appendix E:
2.14	Continuance	The subject will continue further if they meet both criteria: • The settled lens rotation and stability are deemed acceptable for both eyes. • The monocular visual acuity with the study lenses is 0.2 LogMAR or better. If, for either eye, the above-mentioned criteria are not met, the subject will be discontinued (proceed to final evaluation).	
2.15	Post-fit VAS questionnaire	Subjects will complete a VAS questionnaire regarding the initial comfort, vision and handling of the study lenses.	

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Visit 2: Lens fitting #2			
Step	Procedure	Details	Work aid
2.16	Automated Lens tracking	Subjects will complete a session where the lens orientation will be tracked with an automated lens tracking system for a period of 5 minutes following intentional mis-rotation of the study lens from its settled position in the base temporal direction (by 90 degrees for AO1DfA, and by 180 degrees for DT1fA). The mis-rotation of the lens will be performed by the investigator using their finger while wearing suitable disposable medical examination gloves. The mis-rotation and subsequent lens tracking will be done for one eye at a time. Lens orientation will then be measured before and after a series of eye movements in the eight cardinal directions of gaze. <i>Note: Orientation data from the automated lens tracking system will not be entered into EDC, but will instead be provided as an external data set.</i>	Appendix G: Work aid CR-6576
2.17	Lens removal	The subject will remove both lenses. The worn lenses will be discarded unless it is associated with a Product Quality Complaint (PQC) or an Adverse event (AE).	

FINAL EVALUATION

The final evaluation will ordinarily take place immediately following the last scheduled follow-up visit per the study protocol. It may also take place at any point the subject discontinues the study or is terminated from the study.

Final Evaluation			
Step	Procedure	Details	
F.1	Final Exam Form	Indicate if the subject completed the study successfully. If subject discontinued from the study, indicate the reason.	
F.2	Exit Refraction	Perform bare-eye subjective spherocylindrical refraction with a phoropter or a trial frame and record the best-corrected distance visual acuity (OD and OS) to the nearest letter. NOTE: This step is not necessary if the subject was exited due to screen failure.	and Appendix E:
F.3	Exit Slit Lamp Biomicroscopy	Efron Slit Lamp Classification Scale will be used to grade the findings. If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled. This step is not necessary if the subject was exited due to screen failure. NOTE: This step is not necessary if the subject was exited due to screen failure.	Appendix F:

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

7.3. Unscheduled Visits

If, during the investigation, a subject requires an unscheduled visit to the clinical site, the following information will be collected, as appropriate:

- Chief complaint prompting the visit. If the reason is an adverse event, the applicable eCRF for the adverse event must be completed and subject record completed as appropriate.
- Date and time of the visit and all procedures completed at the unscheduled visit.
- Review of adverse events and concomitant medications.
- Documentation of any test article dispensed or collected from the subject, if applicable.
- Slit lamp findings (using the Slit Lamp Classification Scale).

If the Investigator withdraws a subject from the study, the final study visit case report forms must be completed indicating the reason(s) why the subject was withdrawn. The subject record must be completed documenting the date and primary reason for withdrawal and the study CRA notified.

Any ocular and non-ocular Adverse Events that are ongoing at the time of the study visit will be followed by the Investigator, within licensure, until they have resolved, returned to pre-treatment status, stabilized, or been satisfactorily explained. If further treatment i.e., beyond licensure is required, the subject will be referred to the appropriate health care provider.

The following information will be collected during an unscheduled visit.

Unscheduled Visit			
Step	Procedure	Details	
U.1	Chief Complaints	Record the subject's chief complaints for reasons for the unscheduled visit.	
U.2	Adverse Events and Concomitant Medications Review	Review any changes to the subject's medical history or concomitant medications from the previous study visit. Record any changes, and any adverse events.	
U.3	Entrance VA	Record the entrance distance visual acuity (OD, OS and OU) to the nearest letter.	Appendix E: [REDACTED]
U.4	Subjective Sphero-cylindrical Refraction	Perform bare-eye subjective spherocylindrical refraction with a phoropter or a trial frame and record the best-corrected distance visual acuity (OD, OS, and OU) to the nearest letter.	and Appendix E: [REDACTED]
U.5	Slit Lamp Biomicroscopy	Efron Slit Lamp Classification Scale will be used to grade the findings. If the clearance of the fluorescein needs to be expedited, preservative-free rewetting drops or saline may be instilled.	Appendix F: [REDACTED]
U.6	Dispensing (if applicable)	If the subject requires additional lenses to complete the wear period and is eligible to do so, provide additional lenses per the dispensing instructions given in the detailed study procedures.	
U.7	Exit Visual Acuity	Record the subject's exit distance visual acuity (OD, OS and OU) to the nearest letter.	Appendix E: [REDACTED]

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

7.4. Laboratory Procedures

Not Applicable

8. SUBJECTS COMPLETION/WITHDRAWAL

8.1. Completion Criteria

Subjects are considered to have completed the study if they:

- provided informed consent.
- they are eligible.
- have not withdrawn/discontinued from the study for any reason described in section .
- completed all visits through the final visit (Visit 2).
- If all visits were completed but an additional visit is considered necessary for subject care, follow the requirements for unscheduled visits in section .

8.2. Withdrawal/Discontinuation from the Study

A subject will be withdrawn from the study for any of the following reasons:

- Subject withdrawal of consent.
- Subject not compliant to protocol
- Subject lost to follow-up.
- Subject no longer meets eligibility criteria (e.g. the subject becomes pregnant).
- Subject develops significant or serious adverse events necessitating discontinuation of study lens wear
- Subjects who have experienced a Corneal Infiltrative Event (CIE).
- Investigator's clinical judgment regarding the subject safety reasons (that it is in the best interest of the subject to stop treatment).
- Subject missed any study visits
- Subject not compliant with study lens wear schedule
- Subject not successfully dispensed due to lack of efficacy and safety including poor vision, poor comfort or unacceptable fit.

For discontinued subjects, the Investigator will:

- Complete the current visit (scheduled or unscheduled).
- Complete the Final Evaluation, indicating the reason that the subject was discontinued from the study.
- Record the spherocylindrical refraction with best corrected distance visual acuity.
- Collect used test article(s) (worn or brought to the visit) from the subject and discard them, unless otherwise stated in section 7.2.
- Collect all unused test article(s) from the subject.
- Make arrangements for subject care, if needed, due to their study participation

Additional subjects may be enrolled if a subject discontinues from the study prematurely.

In cases where a subject is lost to follow-up, every possible effort must be made to contact the subject and determine the reason for discontinuation/withdrawal. The measures taken to follow up must be documented including two written attempts and a certified letter (or equivalent) as the final attempt.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION

Concomitant medications will be documented during screening and updated during the study. Disallowed concomitant interventions for this study include ocular medications of any kind, or any systemic medications that would normally contraindicate contact lens wear or may otherwise compromise study endpoints.

9.1. Systemic Medications

Certain systemic medications are known to have a higher likelihood to interfere with contact lens wear, chiefly by disrupting the tear film.

A summary of disallowed systemic medications is shown in . Subjects with a history of taking these medications will be allowed to enroll only if:

- The medications have been taken on a continual, routine basis for at least 6 months, and
- The subject has demonstrated successful contact lens wear during this time.

Or:

- The subject was taking the medication on a temporary basis and ceased taking that medication at least 2 weeks prior to signing the informed consent (this is considered sufficient time for the medication to have left the body prior to enrollment).

Subjects with a history of taking medications listed in on a long-term, routine basis for less than 6 months will not be allowed to participate in the study.

Table 4: Disallowed systemic medications

Class of Drug	Common Indication(s)	Common Examples
Estrogens (not including contraceptive medication)	Menopause, osteoporosis, vaginitis	Vagifem, Estrace, Climara, Vivelle-Dot, Premarin, Minivelle, etc.
Anticholinergics	Irritable bowel syndrome, Parkinson's disease, peptic ulcer, cystitis, nasal congestion, cold symptoms, overactive bladder, COPD	Bentyl, Spiriva, Atrovent, Hyosyne, Levsin, Symax Fastab, Symax SL, Homax SL, Cogentin, Transderm Scop, etc.
Beta-blockers	Hypertension, angina, heart attack, migraine, atrial fibrillation, adrenal cancer, essential tumor, glaucoma	Toprol XL, Lopressor, Tenormin, Propranolol, Timoptic, Trandate, Inderal LA, etc.
Psychotropics	Antipsychotic (schizophrenia, mania), antidepression, antiobsessive, antianxiety, mood stabilizer, stimulants (ADHD)	Zoloft, Celexa, Prozac, Lexapro, Effexor, Cymbalta, Ativan, Xanax, Desyrel, Wellbutrin, etc.
Vitamin A analogs	Cystic acne	Isotretinoin

Examples of disallowed systemic antihistamines are given in . Subjects with a history of taking systemic antihistamines will be allowed to enroll only if:

- They have taken antihistamines continuously for at least 2 weeks, and
- They have demonstrated successful wear while taking the medication

Or:

- They stopped taking the medication for at least 2 weeks prior to enrollment.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

Table 5: Disallowed systemic antihistamines

Class of Drug	Common Indication(s)	Common Examples
Antihistamines	Allergic rhinitis, sedation, hives, allergic conjunctivitis, skin allergy, itching, motion sickness	Hydroxyzine, Promethagan, Phenadoz, Vistaril, Claritin, Zyrtec, Astepro, Astelin, Optivar, Allegra, Benadryl, etc.

10. DEVIATIONS FROM THE PROTOCOL

Investigator will notify study sponsor upon identification of a protocol deviation. Protocol deviations must be reported to the sponsor within 24 hours after discovery of the protocol deviation. The Investigator will report deviations per IRB/IEC requirements. All deviations will be tracked, and corrective actions implemented as appropriate.

If it becomes necessary for the Investigator to implement a deviation in order to eliminate an immediate hazard to the trial subject, the Investigator may implement the deviation immediately without notification to the sponsor. Within 24 hours after the implemented deviation, the Investigator must notify and provide the rationale to the Sponsor and, as required, to the IEC/IRB.

If the deviation potentially impacts the safety of subject or changes the technical integrity of the study, then it must be reported to IEC/IRB. This is a "Major Deviation". Deviations that contradict the information contained in the Informed Consent/Assent forms will be considered Major Deviations.

Minor deviations have no substantive effect on subject safety or technical integrity of the study. They are often logistical in nature.

Protocol waivers are prohibited.

lists examples of deviations that will constitute major and minor protocol deviations for this study.

Table 6: Examples of major and minor protocol deviations

Deviation category	Major deviation	Minor deviation
Out-of-window visit (applies to wear periods only, i.e. not washout period)	Visit attended > 2 days out of visit window defined in study procedures	Visit attended ≤ 2 days out of visit window defined in study procedures

In the case of a major protocol deviation, the decision of whether or not the subject will be excluded from the Per-Protocol analysis population will be made at the time of cohort review. The list of major deviations with potential impact on the primary endpoint will be flagged separately and used to define the per protocol population.

11. STUDY TERMINATION

If more than 2 subjects in the investigational soft contact lens group develop serious expected (e.g., definite or probable MK) or unexpected device related adverse events, the study will be suspended. Upon review and consultation with IRB, DMC, and JJVC Safety Management Team, the study may be terminated. This potential stopping rule is established based on our trial involving approximately 200 subjects wearing the investigational soft contact lens for up to 3 years with an assumed MK rate that is below 0.2% per subject-year. The rate of 0.2% per subject-year is the established rate for extended wear lenses in adults, which was requested by the FDA as a criterion for evaluating a contact lens for pediatric use in an FDA response to a pre-IDE submission. To be conservative, 200 independent subject years were used in the calculation. The probability of observing 2 cases or

Clinical Study Protocol

Johnson & Johnson Vision Care, Inc.

more incidents of MK is 0.061, and 3 cases or more incidents of MK is 0.007 (given an MK rate of 0.2% per subject year).

The occurrence of one or more Unanticipated Serious Adverse Device Effect (USADE), or any SAE where the relationship to study agent cannot be ruled out, may result in stopping further dispensing of test article. In the event of a USADE or SAE, the Sponsor may unmask the treatment regimen for the subject(s) and will discuss this with the Investigator before any further subjects are enrolled.

The Sponsor will determine when a study will be stopped. The Principal Investigator always has the discretion to initiate stopping the study based on subject safety or if information indicates the study's results are compromised.

JJVC reserves the right to terminate the study at any time for any reason and will follow the internal applicable quality review process and will notify the IEC/IRB. Additionally, the IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The study can be terminated by the Principal Investigator at the individual clinical site due to specific clinical observations, if in their opinion, after a discussion with JJVC, it is determined that it would be unwise to continue at the clinical site.

JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is determined that an adverse event presents an unreasonable risk, the investigation, or that part of the investigation presenting the risk, will be terminated as soon as possible.

Should the study be terminated (either prematurely or as scheduled), the Investigator will notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements.

12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS

A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication that alleges deficiencies related to the identity, quality, durability, reliability, safety, effectiveness, or performance of test articles after they have been released for clinical trial use.

Potential complaints may come from a variety of sources including but not limited to subjects, clinical research associates (CRA), clinical operations managers (COM), medical monitors, and site personnel, etc. The following are not considered product quality complaints:

- Subject satisfaction inquiries reported via "Subjective Questionnaires" and "Patient Reported Outcomes (PRO)."
- Clinical test articles that are stored improperly or damaged after receipt at the investigational site.
- Lens replacements that occur due to drops/fall-outs.
- Damage deemed by clinicians or clinical staff caused by handling by the user, and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations where there is no deficiency alleged by the subject.

Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be recorded in the EDC system, which will trigger an automatic email notification to the appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in use is not configured to send automatic notifications or when an EDC system is not used, the COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.

Upon receipt of the EDC notification, the COM/CRA will contact the study site to collect additional information which will include:

- Date the complaint was received/recorded in the EDC System (Date of Sponsor Awareness).
- Who received the complaint.
- Study number.
- Clinical site information (contact name, site ID, telephone number).
- Lot number(s).

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

- Unique Subject Identifier(s).
- Indication of who first observed complaint (site personnel or subject).
- OD/OS indication, along with whether the lens was inserted.
- Any related AE number if applicable.
- Detailed complaint description (scheduled/unscheduled visit, wear time, symptoms, resolution of symptoms, etc.).
- Eye Care Provider objective (slit lamp) findings if applicable.
- Confirmation of product availability for return (and tracking information, if available), or rationale if product is not available for return [REDACTED]

Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel to determine if it is an Adverse Event/Serious Adverse Event (AE/SAE). If the complaint results in an AE/SAE, the COM/CRA, or trained site personnel will follow section 13 of this protocol. If the AE/SAE was potentially the result of a product quality related deficiency, these procedures also apply and will be executed in parallel.

In some cases, a PQC form may be generated in EDC by the site in error. In this event, the PQC forms will be marked "Intentionally Left Blank" or "ILB". Justification for ILB must be documented.

13. ADVERSE EVENTS

13.1. Definitions and Classifications

Adverse Event (AE) – An AE is “any untoward medical occurrence, unintended disease or injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the investigational medical device and whether anticipated or unanticipated.”

NOTE: This definition includes events related to the investigational medical device or the comparator, and to the procedures involved. For users or other persons, this definition is restricted to events related to investigational medical devices.¹

An AE includes any condition (including a pre-existing condition) that:

1. Was not present prior to the study, but appeared or reappeared following initiation of the study.
2. Was present prior to the study but worsened during the study. This would include any condition resulting from concomitant illnesses, reactions to concomitant medications, or progression of disease states.

NOTE: Pregnancy must be documented as an adverse event and must be reported to the clinical monitor and to the Sponsor immediately upon learning of the event.

Serious Adverse Event (SAE) – An SAE is any adverse event that led to any of the following:

- Death
- Serious deterioration in the health of the subject that resulted in any of the following:
 - Life-threatening illness or injury
 - Permanent or persistent impairment of a body structure or a body function
 - Hospitalization or prolongation of patient hospitalization
 - Medical or surgical intervention to prevent life-threatening illness or injury or permanent impairment to a body structure or a body function.
 - Chronic disease
- Foetal distress, foetal death or a congenital physical or mental impairment or birth defect.

Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not limited to:

- Microbial Keratitis (MK)
- Iritis (including cells in the anterior chamber)
- Permanent decrease in best spectacle corrected visual acuity equivalent to 2 acuity lines or greater
- Central Corneal Opacity
- Central Corneal Neovascularization

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

- Uveitis
- Endophthalmitis
- Hypopyon
- Hyphemia
- Penetration of Bowman's Membrane
- Persistent Epithelial Defect
- Limbal cell Damage leading to Conjunctivalization

Significant Adverse Events – are defined as events that are symptomatic and warrant discontinuation (temporary or permanent) of the contact lens wear

Diagnoses and conditions that are considered Ocular Significant Adverse Events include, but not limited to the following:

- Contact Lens Induced Peripheral Ulcer (CLPU)
- Significant Infiltrative Events (SIE)
- Superior Epithelial Arcuate Lesions (SEALs)
- Any Temporary Loss of > 2 Lines of BSCVA
- Other grade 3 or higher corneal findings, such as abrasions or edema
- Non-contact lens related corneal events - e.g. Epidemic Keratoconjunctivitis (EKC)
- Asymptomatic Corneal Scar
- Any corneal event which necessitates temporary lens discontinuation > 2 weeks

Non-Significant Adverse Events – are defined as those events that are usually asymptomatic and usually do not warrant discontinuation of contact lens wear but may cause a reduction in wear time. However, the Investigator may choose to prescribe treatment as a precautionary measure.

Diagnoses and conditions that are considered Ocular Non-Significant Adverse Events include, but not limited to the following:

- Non-significant Infiltrative Event (NSIE)
- Contact Lens Papillary Conjunctivitis (CLPC)
- Superficial Punctate Keratitis (SPK)
- Conjunctivitis: Bacterial, Viral, Allergic
- Blepharitis
- Meibomianitis
- Contact Dermatitis
- Localized Allergic Reactions
- Hordeolum
- Any corneal event not explicitly defined as serious or significant adverse event, which necessitates temporary lens discontinuation < 2 weeks

Adverse Device Effect (ADE) – An ADE is an “adverse event related to the use of an investigational medical device.”

NOTE 1: This definition includes adverse events resulting from insufficient or inadequate instructions for use, deployment, implantation, installation, or operation, or any malfunction of the investigational medical device.

NOTE 2: This definition includes any event resulting from use error or from intentional misuse of the investigational medical device.

NOTE 3: This includes ‘comparator’ if the comparator is a medical device.

Serious Adverse Device Effect (SADE) – Any adverse device effect that has resulted in any of the consequences characteristic of a serious adverse event.

Unanticipated Serious Adverse Device Effect (USADE): serious adverse device effect (SADE) which by its nature, incidence, severity or outcome has not been identified in the current risk assessment. [USADE is synonymous with UADE below from the United States (US) Code of Federal Regulations (CFR)³.]

NOTE 1: Anticipated serious adverse device effect (ASADE) is an effect which by its nature, incidence, severity or outcome has been identified in the risk assessment.

Clinical Study Protocol

Johnson & Johnson Vision Care, Inc.

Unanticipated Adverse Device Effect (UADE) – A UADE is any serious adverse effect on health or safety or any life-threatening problem or death caused by, or associated with, the test article, if that effect, problem, or death was not previously identified in nature, severity, or degree of incidence in the investigational plan, Investigator's Brochure or protocol, or any other unanticipated serious problem associated with the test article that relates to the rights, safety and welfare of subjects. [UADE is synonymous with USADE above from ISO 14155¹.]

13.2. Assessing Adverse Events

In conjunction with the medical monitor, the Investigator will evaluate adverse events to ensure the events are categorized correctly. Elements of categorization will include:

- Seriousness/Classifications (see definition in section 13.1).
- Causality or Relatedness – i.e. the relationship between the test article, study treatment or study procedures and the adverse event (not related, unlikely related, possibly related, or related)
- Adverse Event Severity – Adverse event severity is used to assess the degree of intensity of the adverse event (mild, moderate, or severe)
- Outcome – not recovered or not resolved, recovering or resolving, recovered or resolved with sequelae, recovered or resolved, death related to adverse event, or unknown.
- Actions Taken – none, temporarily discontinued, permanently discontinued, or other.

Causality Assessment

Causality Assessment – A determination of the relationship between an adverse event and the test article, study treatment, or the study procedures. The test article, study treatment, or study procedures relationship for each adverse event should be determined by the investigator using these explanations:

- Not Related- An adverse event that is not related to the use of the test article, study treatment, or study procedures.
- Unlikely Related – An adverse event for which an alternative explanation is more likely, e.g. concomitant treatment, concomitant disease(s), or the relationship of time suggests that a causal relationship is not likely.
- Possibly Related – An adverse event that might be due to the use of the test article, or to the study treatment or study procedures. An alternative explanation, e.g. concomitant treatment, concomitant disease(s), is inconclusive. The relationship in time is reasonable. Therefore, the causal relationship cannot be excluded.
- Related – An adverse event that is listed as a possible adverse effect (device) or adverse reaction (drug) and cannot be reasonably explained by an alternative explanation, e.g. concomitant treatment of concomitant disease(s). The relationship in time is very suggestive, e.g. it is confirmed by de-challenge and re-challenge.

Severity Assessment

Severity Assessment – A qualitative assessment of the degree of intensity of an adverse event as determined by the Investigator or reported to him/her by the subject. The assessment of severity is made irrespective of test article, study treatment or study procedure relationship or seriousness of the event and should be evaluated according to the following scale:

- Mild – Event is noticeable to the subject but is easily tolerated and does not interfere with the subject's daily activities.
- Moderate – Event is bothersome, possibly requiring additional therapy, and may interfere with the subject's daily activities.
- Severe – Event is intolerable, necessitates additional therapy or alteration of therapy and interferes with the subject's daily activities.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

13.3. Documentation and Follow-Up of Adverse Events

The recording and documenting of adverse events (ocular and non-ocular) begin when the subjects are exposed to the test article, study treatment or study procedure. Adverse events reported before the use of test article, start of study treatment, or study procedures will be recorded as medical history. However, if the condition deteriorates at any time during the study it will be recorded and reported as an AE. Untoward medical events reported after the subject's exit from the study will be recorded as adverse events at the discretion of the Investigator.

Upon finding an adverse event, the Principal Investigator will document the condition in the subject record and in the eCRFs and complete the Adverse Event eCRF.

Complete descriptions of all adverse events must be available in the subject record. All Adverse Events including local and systemic reactions not meeting the criteria for "serious adverse events" shall be captured on the appropriate case report form or electronic data system. All adverse events occurring while the subject is enrolled in the study must be documented appropriately regardless of relationship.

It is the Investigator's responsibility to maintain documentation of each reported adverse event. All adverse events will be followed in accordance with applicable licensing requirements. Such documentation will include the following:

- Adverse event (diagnosis not symptom).
- Drawings or photographs (where appropriate) that detail the finding (e.g., size, location, and depth, etc.).
- Date the clinical site was notified.
- Date and time of onset.
- Date and time of resolution.
- Adverse event classification, severity, and relationship to test articles, as applicable.
- Treatment regimen instituted (where appropriate), including concomitant medications prescribed, in accordance with applicable licensing requirements.
- Any referral to another health care provider if needed.
- Outcome, ocular damage (if any).
- Likely etiology.
- Best corrected visual acuity at the discovery of the event and upon conclusion of the event, if the AE is related to the visual system.

Upon discovery of an AE that is deemed 'possibly related' or 'related' to the test article or study procedures (whether related to the visual system or not), an AE review form [REDACTED] must be completed. Additional dated and initialed entries should be made at follow-up evaluations. Separate forms must be completed for each eye if the AE is bilateral.

In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate Assessment eCRF. Where necessary, a culture of the corneal lesion will be collected to determine if the infection is microbial in nature. If cultures are collected, the date of culture collection and laboratory utilized will be recorded.

Changes in the severity of an AE shall be documented to allow an assessment of the duration of the event at each level of intensity to be performed. Adverse events characterized as intermittent require documentation of the onset and duration of each episode. Changes in the assessment of relationship to the Test Article shall also be clearly documented.

Subjects who present with an adverse event shall be followed by the Investigator, within licensure, until all signs and symptoms have returned to pre-treatment status, stabilized, or been satisfactorily resolved. If further treatment beyond licensure is required, the subject will be referred to the appropriate health care provider. The Investigator will use his/her clinical judgment as to whether a subject reporting with an adverse event will continue in the study. If a subject is discontinued from the study, it will be the responsibility of the Investigator to record the reason for discontinuation. The Investigator will also document the adverse event appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse events related to the test article, study treatment or study procedures, as of the final study visit date, should be followed to resolution of the adverse event or until referral to an appropriate health care provider, as recommended by the Investigator. Non-ocular adverse events

Clinical Study Protocol

Johnson & Johnson Vision Care, Inc.

that are not related to the test article, study treatment, or study procedures may be recorded as “ongoing” without further follow-up.

13.4. Reporting Adverse Events

The Investigator will notify the Sponsor of an adverse event by EDC System, e-mail, or telephone as soon as possible and no later than 24 hours from discovery for any serious /significant adverse events, and 2 days from discovery for any non-significant adverse event. In addition, a written report will be submitted by the Principal Investigator to the IEC/IRB according to their requirements. The report will comment whether the adverse event was considered to be related to the test article, study treatment or study procedures.

Reporting Adverse Events to Sponsor

Serious/Significant Adverse Events

The Investigator will inform the sponsor of all serious/significant adverse events occurring during the study period as soon as possible by EDC System, e-mail or, telephone, but no later than 24 hours following discovery of the event. The Investigator is obligated to pursue and obtain information requested by the Sponsor in addition to that information reported on the eCRF. All subjects experiencing a serious/significant adverse event must be followed up and all outcomes must be reported.

When medically necessary, the Investigator may break the randomization code to determine the identity of the treatment that the subject received. The Sponsor and study monitor should be notified prior to unmasking the test articles.

In the event of a serious/significant adverse event, the Investigator must:

- Notify the Sponsor immediately.
- Obtain and maintain in the subject's records all pertinent medical information and medical judgment for colleagues who assisted in the treatment and follow-up of the subject.
- Provide the Sponsor with a complete case history which includes a statement as to whether the event was or was not related to the use of the test article.
- Notify the IEC/IRB as required by the IEC/IRB reporting procedure according to national regulations.

Unanticipated (Serious) Adverse Device Effect (UADE)

In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no later than 24 hours after the Investigator first learns of the effect. This report is in addition to the immediate notification mentioned above.

The Sponsor must conduct an evaluation of the UADE and must report the results of the evaluation to FDA, the IEC/IRB and participating Investigators within 10 working days after the Sponsor first receives notification of the effect.

Non-Serious Adverse Events

All non-serious adverse events, including non-serious adverse device effects, will be reported to the sponsor by the Investigator no later than 2 days from discovery.

Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities

Adverse events that meet the IEC/IRB requirements for reporting must be reported within the IEC/IRB's written guidelines. Each clinical site will refer to and follow any guidelines set forth by their Approving IEC/IRB. Each clinical site will refer to and follow any guidelines set forth by their local governing Health Authorities.

The Sponsor will report applicable Adverse Events to the local health authorities according to the written guidelines, including reporting timelines.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

13.5. Event of Special Interest

None

13.6. Reporting of Pregnancy

Subjects reporting pregnancy (by self-report) during the study will be discontinued after the event is recorded as an Adverse Event. Once discontinued, pregnant subject and their fetuses will not be monitored for study related purposes. Pregnant subjects are not discontinued from contact lens or solution related studies for safety concerns, but due to general concerns relating to pregnancy and contact lens use. Specifically, pregnant women are discontinued due to fluctuations in refractive error and/or visual acuity that occur secondary to systemic hormonal changes, and not due to unforeseen health risks to the mother or fetus.

14. STATISTICAL METHODS

14.1. General Considerations

Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. A general description of the statistical methods to be implemented in this clinical trial is outlined below.

Descriptive summary tables (descriptive statistics and/or frequency tables) will be provided for all demographic and baseline characteristics, efficacy variables and safety variables. For continuous endpoints, the descriptive statistics will include the number of subjects and/or eyes (as appropriate), mean, standard deviation (SD), median, and minimum and maximum. For binary or categorical endpoints, the frequency distribution with the number and percentage of subjects and/or eyes (as appropriate) in each category will be calculated. Graphic displays may also be used to summarize the data. Unscheduled visits will be summarized separately.

All data summaries and statistical analyses will be performed using the SAS software Version 9.4 or higher (SAS Institute, Cary, NC)⁵.

14.2. Sample Size Justification

This study was not designed or powered to test any statistical hypotheses with respect to distance (4m) visual acuity. As this will be the first study that will utilize the tracking software (Open Source Physics – OSP) a total of 5 subjects (10 eyes) to complete the study was based on clinical considerations and operational feasibility. A total of 5 subjects under a 2x2 crossover design provides sufficient data to evaluate the efficiency of this new software.

14.3. Analysis Populations

Intention-to-Treat (ITT) Population:

Intention-to-treat population will include all randomized subjects. Subjects will be analyzed as per planned randomized treatment.

Safety Population:

All subjects who are administered any study intervention. Subjects will be analyzed as per actual treatment received.

Per-Protocol Population:

All subjects who successfully complete all visits and do not substantially deviate from the protocol as determined by the trial cohort review committee prior to database hard lock. Justification for the exclusion of subjects with protocol deviations from the per-protocol population set will be documented in a memo to file.

14.4. Level of Statistical Significance

Not applicable. No hypothesis testing will be performed for any endpoints in this study.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

14.5. Statistical Analyses

Handling of Missing Data

All data summaries and statistical analysis will be conducted using the observed case data without multiple imputation. The count of missing data will be provided in each listing and table provided.

14.6. Efficacy Analyses

All efficacy endpoints will be summarized for both the ITT and per-protocol population using observed case data without multiple imputation.

Primary Efficacy Endpoint

1. Distance Visual Acuity

Distance (6m) monocular HLHC logMAR visual acuity at fitting will be summarized and presented only descriptively by lens type and timepoint (if applicable). Summary statistics are described in section 14.1

Secondary Efficacy Endpoint

Not applicable.

Other Efficacy Endpoints

1. Lens orientation measured over time with an automated lens tracking system following intentional misalignment Data resulting from the processing of the videos of each subject eye (for each lens), will be summarized by parameter (rotation error magnitude [range: 0° to 180°] and rotation error direction [base temporal or nasal]). The video processed will be approximately 5 minutes per eye per lens. The tracking software will measure the parameters at 5-second intervals, totaling for a plan of 60 observations per eye per lens. Rotation error magnitude is a continuous data point while the rotation error direction is nominal categorical data. Signed rotation will be derived based on rotation error magnitude and direction and will be included as part of the external data file detailed in section 15. Parameter data (rotation error magnitude, signed rotation, and rotation direction) reported (or derived) from the automated tracking system will be summarized as per section 14.1.

2. Lens orientation recorded with an automated lens tracking system following eye movements
In addition to collecting rotation error magnitude and direction following intentional misalignment, rotation error magnitude and direction will be recorded in each of the 8 cardinal gaze directions before and after eye movement. The signed rotation will be derived in the same manner as described above. Summaries will be provided for each parameter (rotation error magnitude, signed rotation, and rotation direction), timepoint (before and after eye movement) and gaze separately. Additional summaries will be provided for the 8 gazes combined.

The 8 cardinal gazes are:

- Up and to the right
- Upward
- Up and to the left
- Right
- Left
- Down and to the right
- Downward
- Down and to the left

3. Settling Time following intentional misalignment

The time (in seconds) required for the lens to settle (defined as returning to within 5 degrees of initial settled position) after intentional misalignment will be presented descriptively and summarized separately for each study lens. Summary statistics are described in section 14.1.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

4. Toric Lens Orientation

The distribution (counts, percentages) of eyes for the toric Orientation (in degrees) at 1- and 3-minutes after lens insertion will be summarized at fitting and by lens type. Summary statistics are described in section 14.1.

5. Subjective Vision, Comfort and Handling Scores

Vision, comfort, and handling items will be summarized separately and presented only descriptively by lens type and timepoint (if applicable). Summary statistics are described in section 14.1.

14.7. Safety Analyses

All safety endpoints will be summarized for the safety population using observed case data.

Primary Safety Endpoint

Not applicable.

Secondary Safety Endpoint

Not applicable.

Other Safety Endpoints

1. Slit Lamp Findings

Slit Lamp Findings (SLF) related to study lens wear will be assessed for each eye at all study visits (scheduled and unscheduled). SLFs will be evaluated and graded using the Efron Grading scale. The Efron grading scale is interval continuous from 0 to 4, where 0 represents the absence of findings and findings > 0 representing successively worse findings. Slit lamp will be used to assess the following:

- Corneal infiltrates
- Conjunctival redness
- Limbal redness
- Corneal neovascularization
- Epithelial microcysts
- Corneal oedema
- Corneal staining
- Location of staining
- Conjunctival staining
- Blepharitis
- Meibomian Gland dysfunction
- Mucin ball

Each study lens and parameter will be summarized separately and presented descriptively.

2. Adverse events (AEs)

Details for AEs will be provided through listings. This listing will include both ocular and non-ocular.

14.8. Interim Analyses

Not applicable.

14.9. Procedure for Reporting Deviations from Statistical Plan

The analysis will be conducted according to that specified in above sections. There are no known reasons for which it is planned to deviate from these analysis methods. If for any reason a change is made, the change will be documented in the study report along with a justification for the change.

15. DATA HANDLING AND RECORD KEEPING/ARCHIVING

15.1. Electronic Case Report Form/Data Collection

The data for this study will be captured on electronic case report forms (eCRFs) using a Sitero EDC system. An authorized data originator will enter study data into the eCRFs using the EDC system. Data collected on equipment that is not captured in EDC will be formatted to the specification of the JJVC database manager and sent to JJVC for analysis.

External data sources for this study include: Video files and Excel data files for lens orientation analysis per subject. Each video recording will show a single eye and its surrounding eyelid area (see Appendix G for example) without having personally identifiable information in the image or the filename. The video files will be provided in a standard video format (eg. mpeg). Video files are processed using tracking software (Open Source Physics – OSP) to estimate the lens orientation over a 5-minute period of recovery from intentional misalignment from the settled position. The rotation error direction and magnitude relative to two reference positions (relative to 6 o'clock position, and relative to initial settled position) will be provided. The signed rotation will be derived using rotation error magnitude and direction. Data is planned to be provided at 5 second increments, but alternative increments may be found to be necessary once data collection commences.

Additionally, lens orientation (direction and magnitude of rotation error relative to 6 o'clock position, and relative to initial settled position) following eye movements in 8 directions of gaze will be provided in a separate Excel spreadsheet.



The clinical data will be recorded on dedicated eCRFs specifically designed to match the study procedures for each visit. Only specifically delegated staff can enter data on a CRF. Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by the Investigator. The sponsor or sponsor's representatives will be authorized to gain access to the subject recordation for the purposes of monitoring and auditing the study.

Edit checks, electronic queries, and audit trails are built into the system to ensure accurate and complete data collection. Data will be transmitted from the clinical site to a secure central database as forms are completed or updated, ensuring information accuracy, security, and confidentiality. After the final database lock, the Investigator will be provided with Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF format for all of the study data. The IPP must be retained in the study files as a certified copy of the source data for the study.

The content and structure of the eCRFs are compliant with ISO14155:2020.¹

15.2. Subject Record

At a minimum, subject record should be available for the following:

- subject identification
- eligibility
- study identification
- study discussion
- provision of and date of informed consent
- visit dates
- results of safety and efficacy parameters as required by the protocol
- a record of all adverse events
- follow-up of adverse events
- medical history and concomitant medication
- test article receipt/dispensing/return records
- date of study completion

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

- reason for early discontinuation of test article or withdrawal from the study, if applicable

The subject record is the eCRF or an external record. The author of an entry in the subject record must be identifiable. The first point of entry is considered to be the source record.

Adverse event notes must be reviewed and initialed by the Investigator.

15.3. Trial Registration on ClinicalTrials.gov

This study will be registered on ClinicalTrials.gov by the sponsor.

16. DATA MANAGEMENT

16.1. Access to Source Data/Document

The Investigator/Institution will permit trial-related monitoring, audits, IEC/IRB review and regulatory inspection(s) by providing direct access to source data/documents. Should the clinical site be contacted for an audit by an IEC/IRB or regulatory authority, JJVC must be contacted and notified in writing within 24 hours.

16.2. Confidentiality of Information

Information concerning the investigational product and patent application processes, scientific data or other pertinent information is confidential and remains the property of JJVC. The Investigator may use this information for the purposes of the study only. It is understood by the Investigator that JJVC will use information developed in this clinical study in connection with the development of the investigational product and therefore may disclose it as required to other clinical investigators and to regulatory agencies. In order to allow the use of the information derived from this clinical study, the Investigator understands that he/she has an obligation to provide complete test results and all data developed during this study to the Sponsor.

16.3. Data Quality Assurance

Steps will be taken to ensure the accuracy and reliability of data, including the selection of qualified investigators and appropriate clinical sites and review of protocol procedures with the Principal Investigator. The Principal Investigator, in turn, must ensure that all Sub-Investigators and clinical site personnel are familiar with the protocol and all study-specific procedures and have appropriate knowledge of the study article.

Training on case report form completion will be provided to clinical site personnel before the start of the study. The Sponsor will review case report forms for accuracy and completeness remotely during the conduct of the study, during monitoring visits, and after transmission to data management. Any data discrepancies will be resolved with the Investigator or designee, as appropriate.

Quality Assurance representatives from JJVC may visit clinical sites to review data produced during the study and to access compliance with applicable regulations pertaining to the conduct of clinical trials. The clinical sites will provide direct access to study-related source data/documents and reports for the purpose of monitoring and auditing by JJVC and for inspection by local and regulatory authorities.

16.4. Data Monitoring Committee (DMC)

Not applicable

17. CLINICAL MONITORING

The study monitors will maintain close contact with the Principal Investigator and the Investigator's designated clinical site personnel. The monitor's responsibilities will include:

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

- Ensuring that the investigation is being conducted according to the protocol, any subsequent versions, and regulatory requirements are maintained.
- Ensuring the rights and wellbeing of subjects are protected.
- Ensuring adequate resources, including facilities, laboratories, equipment, and qualified clinical site personnel.
- Ensuring that protocol deviations are documented with corrective action plans, as applicable.
- Ensuring that the clinical site has sufficient test article and supplies.
- Clarifying questions regarding the study.
- Resolving study issues or problems that may arise.
- Reviewing of study records and source documentation verification in accordance with the monitoring plan.

18. ETHICAL AND REGULATORY ASPECTS

18.1. Study-Specific Design Considerations

Potential subjects will be fully informed of the risks and requirements of the study, and during the study, subjects will be given any new information that may affect their decision to continue participation. Subjects will be told that their consent to participate in the study is voluntary and may be withdrawn at any time with no reason given and without penalty or loss of benefits to which they would otherwise be entitled. Subjects will only be enrolled if the subject is fully able to understand the risks, benefits, and potential adverse events of the study and provide their consent voluntarily.

18.2. Investigator Responsibility

The Principal Investigator is responsible for ensuring that the clinical study is performed in accordance with the signed agreement, the investigational plan, according to ISO 14155:2020,¹ and applicable regulatory requirements. GCP is an international ethical and scientific quality standard for designing, conducting, recording, and reporting studies that involve the participation of human subjects. Compliance with this standard provides public assurance that the rights, safety, and well-being of study subjects are protected, consistent with the principles of the Declaration of Helsinki 64th WMA General Assembly 2013² and that the clinical study data are credible. The Investigator must maintain clinical study files in accordance with applicable regulatory requirements.

18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB)

Before the start of the study, the Investigator (or Sponsor when applicable) will provide the IEC/IRB with current and complete copies of the following documents (where applicable):

- Final protocol.
- Sponsor-approved informed consent form (and any other written materials to be provided to the subjects)
- Investigator's Brochure (or equivalent information).
- Sponsor-approved subject recruitment materials.
- Information on compensation for study-related injuries or payment to subjects for participation in the study.
- Investigator's curriculum vitae, clinical licenses, or equivalent information (unless not required, as documented by IEC/IRB).
- Information regarding funding, name of the Sponsor, institutional affiliations, other potential conflicts of interest, and incentives for subjects.
- Any other documents that the IEC/IRB requests to fulfill its obligation.

This study will be undertaken only after IEC/IRB has given full approval of the final protocol, the informed consent form, applicable recruiting materials, and subject compensation programs, and the Sponsor has received a copy of this approval. This approval letter must be dated and must clearly identify the documents being approved.

Clinical Study Protocol

Johnson & Johnson Vision Care, Inc.

During the study, the Investigator (or Sponsor when applicable) will send the following documents to the IEC/IRB for their review and approval, where appropriate:

- Protocol revisions
- Revision(s) to informed consent form and any other written materials to be provided to subjects
- If applicable, new or revised subject recruitment materials approved by the Sponsor
- Revisions to compensation for study-related injuries or payment to subjects for participation in the study
- Investigator's Brochure revisions
- Summaries of the status of the study (at least annually or at intervals stipulated in guidelines of the IEC/IRB)
- Reports of adverse events that are serious, unanticipated, and associated with the test articles, according to the IRB's requirements
- New information that may adversely affect the safety of the subjects or the conduct of the study
- Major protocol deviations as required by the IEC/IRB
- Report of deaths of subjects under the Investigator's care
- Notification if a new Investigator is responsible for the study at the clinical site
- Any other requirements of the IEC/IRB

For protocol revisions that increase subject risk, the revisions and applicable informed consent form revisions must be submitted promptly to the IEC/IRB for review and approval before implementation of the change(s).

At least once a year, the IEC/IRB will review and reapprove this clinical study. This request should be documented in writing.

At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB about the study completion. Documentation of this notification must be retained at the clinical site and a copy provided to the CRO or Sponsor as applicable.

18.4. Informed Consent

Each subject, or their representative, must give written consent according to local requirements after the nature of the study has been fully explained. The consent form must be signed before performance of any study-related activity. The consent form that is used must be approved by both the Sponsor and by the reviewing IEC/IRB. The informed consent is in accordance with principles that originated in the Declaration of Helsinki,³ and ISO 14155:2020¹ guidelines, applicable regulatory requirements, and Sponsor Policy.

Before entry into the study, the Investigator or an authorized member of the clinical site personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, and potential hazards of the study, and any discomfort it may entail. Subjects will be informed that their participation is voluntary and that they may withdraw their consent to participate at any time.

The subject will be given sufficient time to read the informed consent form and the opportunity to ask questions. After this explanation and before entry into the study, consent should be appropriately recorded by means of the subject's dated signature. After having obtained the consent, a copy of the informed consent form must be given to the subject.

18.5. Privacy of Personal Data

The collection, processing and disclosure of personal data and medical information related to the Study Subject, and personal data related to Principal Investigator and any clinical site personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to compliance with the Health Information Portability and Accountability Act (HIPAA) in the United States and other applicable personal data protection and security laws and regulations. Appropriate measures will be employed to safeguard these data, to maintain the confidentiality of the person's related health and medical information, to properly inform the concerned persons about the collection and processing of their personal data, to grant them reasonable access to their personal data and to prevent access by unauthorized persons.

Clinical Study Protocol

Johnson & Johnson Vision Care, Inc.

All information obtained during the course of the investigation will be regarded as confidential. All personal data gathered in this trial will be treated in strictest confidence by Investigators, monitors, Sponsor's personnel and IEC/IRB. No data will be disclosed to any third party without the express permission of the subject concerned, with the exception of Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of their investigation related activities that, as part of the investigation will have access to the CRFs and subject records.

The collection and processing of personal data from subjects enrolled in this study will be limited to those data that are necessary to investigate the efficacy, safety, quality, and utility of the investigational product(s) used in this study.

These data must be collected and processed with adequate precautions to ensure confidentiality and compliance with applicable data privacy protection laws and regulations.

The Sponsor ensures that the personal data will be:

- processed fairly and lawfully.
- collected for specified, explicit, and legitimate purposes and not further processed in a way incompatible with these purposes.
- adequate, relevant, and not excessive in relation to said purposes.
- accurate and, where necessary, kept current.

Explicit consent for the processing of personal data will be obtained from the participating subject before collection of data. Such consent should also address the transfer of the data to other entities and to other countries.

The subject has the right to request through the Investigator access to his personal data and the right to request rectification of any data that are not correct or complete. Reasonable steps should be taken to respond to such a request, taking into consideration the nature of the request, the conditions of the study, and the applicable laws and regulations.

Appropriate technical and organizational measures to protect the personal data against unauthorized disclosures or access, accidental or unlawful destruction, or accidental loss or alteration must be put in place. Sponsor personnel whose responsibilities require access to personal data agree to keep the identity of study subjects confidential.

19. STUDY RECORD RETENTION

In compliance with the ISO 14155:2020,¹ guidelines, the Investigator/Institution will maintain all CRFs and all subject records that support the data collected from each subject, as well as all study documents as specified in ISO 14155:2020,¹ and all study documents as specified by the applicable regulatory requirement(s). The Investigator/Institution will take measures to prevent accidental or premature destruction of these documents.

Essential documents must be retained until at least two (2) years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or until at least two (2) years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents will be retained for a longer period if required by the applicable regulatory requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the Investigator/Institution as to when these documents no longer need to be retained.

If the responsible Investigator retires, relocates, or for other reasons withdraws from the responsibility of keeping the study records, custody must be transferred to a person who will accept the responsibility. The Sponsor must be notified in writing of the name and address of the new custodian. Under no circumstance shall the Investigator relocate or dispose of any study documents before having obtained written approval from the Sponsor.

If it becomes necessary for the Sponsor or the appropriate regulatory authority to review any documentation relating to this study, the Investigator must permit access to such reports.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

If the Investigator has a question regarding retention of study records, he/she should contact JJVC.

20. FINANCIAL CONSIDERATIONS

Remuneration for study services and expenses will be set forth in detail in the Clinical Research Agreement. The Research Agreement will be signed by the Principal Investigator and a JJVC management representative prior to study initiation.

JJVC reserves the right to withhold remuneration for costs associated with protocol violations such as:

- Continuing an ineligible subject in the study.
- Scheduling a study visit outside the subject's acceptable visit range.

JJVC reserves the right to withhold final remuneration until all study related activities have been completed, such as:

- Query resolution.
- Case Report Form signature.
- Completion of any follow-up action items.

21. PUBLICATION

The study will be listed on clinicaltrials.gov.

22. REFERENCES

1. ISO 14155:2020: Clinical Investigation of Medical Devices for Human Subjects — Good Clinical Practice. Available at: <https://www.iso.org/standard/71690.html>
2. Declaration of Helsinki - Ethical principles for Medical Research Involving Human Subjects. Available at: <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>
3. United States (US) Code of Federal Regulations (CFR). Available at: <https://www.gpo.gov/fdsys/browse/collectionCfr.action?collectionCode=CFR>
4. International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP). Available at: <https://www.ich.org/page/efficacy-guidelines>
5. SAS Institute Inc: SAS® 9.4 Statements: Reference, Third Edition. Cary, NC SAS Institute Inc; 2014.
6. Health Information Portability and Accountability Act (HIPAA). Available at: <https://www.hhs.gov/hipaa/for-professionals/privacy/index.html>

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX B: PATIENT INSTRUCTION GUIDE

The Patient Instruction Guide (PIG) will be provided separately.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)

1. ACUVUE® OASYS 1-Day for Astigmatism contact lenses from JJVCI
2. Dailies® Total1 for Astigmatism contact lenses from Alcon Inc.

IMPORTANT: This package insert is effective as of May 2020 and applicable to the delefilcon A contact lenses described below. Please read carefully and keep this information for future use.

This package insert is intended for the Eye Care Professional, but should be made available to patients upon request. The Eye Care Professional should provide the patient with appropriate instructions from patient to the patient's prescriber. Alcon also recommends that patients receive a copy of the Patient Instruction Booklet for their prescribed lenses. Copies of this package insert and the Patient Instruction Booklet are available without charge from Alcon by calling Customer Service at 1-800-211-3888 or download from our website at www.alcon.com.



CAUTION: Federal law (United States) restricts this device to sale by or on the order of a licensed Eye Care Professional.

PRODUCT DESCRIPTION

DAILIES TOTAL¹™ for Astigmatism (delefilcon A) soft contact lenses are made of a lens material that is approximately 33% water and 67% (delefilcon A) polymer, a silicone containing hydrogel with added phosphatidylcholine. The core lens material containing 33% water transitions through a water gradient to a hydrogel surface layer that expands 80% water. Lenses contain the color additive copper phthalocyanine, and have a light blue-green tint that makes them easier to see when handling. This package insert applies to DAILIES TOTAL¹™ for Astigmatism lenses with light absorbing chromophores (as identified in "Contents" statement on certain labeling). Benzotriazole UV and UV-VIS absorbing monomers are used to block UV radiation and reduce transmittance of high energy visible light (HEVL) wavelengths in the range from 380 nm to 450 nm.*

Lens Properties

- Refractive Index (hydrated): 1.42
- Light Transmittance: 90% ± 5% for average over 380 to 780 nm
- HEVL Transmittance: < 30% at 420 nm (refer to Figure 1 for transmittance profile)*
- UV Transmittance: rUVA < 1.0 % (average percent transmittance over 280 nm to 315 nm)
rUVA < 10.0 % (average percent transmittance over 315 nm to 380 nm)
- Oxygen Permeability (Dk): 140 barrer units, measured at 35 °C (intrinsic Dk - Coulometric method)
- Water Content: 33% by weight in normal saline

Lens Parameters

- Diameter Range: 13.0 to 15.0 mm
- Power Range: -20.00 to +20.00 D
- Base Curve Range: 8.0 to 9.2 mm

Lens Parameters Available¹

- DAILIES TOTAL¹™ for Astigmatism (delefilcon A)
- Chrom Diameter: 14.5 mm
- Center Thickness: 0.11 mm @ -3.00 D (varies with power)
- Base Curve: 8.6 mm
- Sphere Power: +4.00 to -6.00 D (0.25 D steps); -6.50 to -4.00 D (0.50 D steps)
- Cylinder Power: -0.75 D, -1.25 D, -1.75 D, -2.25 D
- Axial: 10° to 180°, in 10° steps

ACTIONS

When hydrated and placed on the cornea, DAILIES TOTAL¹™ for Astigmatism (delefilcon A) soft contact lenses act as a refracting medium to focus light rays on the retina.

The lenses contain a combination of UV and UV-VIS blocking monomers to help protect against transmission of harmful UV radiation to the cornea and into the eye. For example, a lens with 0.09 mm center thickness (-3.00 D, thinnest projected parameter) blocks 97% of UVA radiation, and 99% of UVB radiation across the spectrum. The lenses reduce high energy visible light (HEVL) radiation reaching the back of the eye by about 33% in the range from 380 nm to 450 nm*. See Figure 1 for the transmittance profile of delefilcon A lenses with light absorbing chromophores (-3.00 D, thinnest projected parameter). The radiation transmittance will be further reduced with increasing lens thickness.

WARNING: UV absorbing contact lenses are NOT substitutes for protective UV absorbing eyewear, such as UV absorbing goggles or sunglasses because they do not completely cover the eye and surrounding area. The patient should continue to use UV absorbing eyewear as directed.


NOTE: Long-term exposure to UV radiation is one of the risk factors associated with cataracts. Exposure is based on a number of factors such as environmental conditions (altitude, geography, cloud cover) and personal factors (extent and nature of outdoor activities). UV-blocking contact lenses help provide protection against harmful UV radiation. However, clinical studies have not been done to demonstrate that wearing UV-blocking contact lenses reduces the risk of developing cataracts or other eye disorders. High energy visible light filtering provided by delefilcon A soft contact lenses with light absorbing chromophores is additive to the natural crystalline lens. There is no demonstrated clinical benefit to a 33% reduction in visible light at wavelengths below 450 nm. The Eye Care Professional should be consulted for more information.

Figure 1 illustrates the transmittance of a lens with 0.09 mm center thickness (-3.00 D, thinnest projected parameter), a human cornea, a human lens, and the combined filtration effect of the contact lens and the human lens on retinal exposure. The shaded regions of the graph represent the integrated attenuation transmittance percentages of the delefilcon A lenses with light absorbing chromophores (-3.00 D, thinnest projected parameter) in the high energy visible light region (380 nm to 450 nm). The overall light attenuation over this region is 33%, with 65% attenuation over the region from 380 nm to 400 nm, and 21% attenuation over the region from 400 nm to 450 nm. This represents the filtration of the contact lens through the central 6 mm portion for a lens with 0.09 mm center thickness.

* See "Note". There is no demonstrated clinical benefit to a 33% reduction in visible light at wavelengths below 450 nm.

(-3.00 D, thinnest projected parameter). Filtration would increase for contact lens powers with higher center thickness.

Wavelength	Percent integrated attenuation transmittance of high energy visible light*
380 nm to 400 nm	65%
400 nm to 450 nm	21%
380 nm to 450 nm	33%



Delefilcon A with light absorbing chromophores: Contact lens with 0.09 mm center thickness measured through central 6 mm portion for the thinnest marketed lens (-3.00 D, thinnest projected parameter). Human Cornea from a 24 year old person as described in Lerman S., *Radiant Energy and the Eye*, MacMillan, New York, 1980, p.53, Figure 2-21. Human crystalline lens from a 25 year old person as described in Walker M., *Hitchcock V.M., Optical Radiation and Visual Health*, CRC Press, Boca Raton, Florida, 1986, p. 18, Figure 5. Combined filtering effect of the contact lens and the natural crystalline lens on retinal exposure.

Figure 1: Transmittance of a DAILIES TOTAL¹™ for Astigmatism (delefilcon A) Contact Lens versus a Human Cornea and a Human Crystalline Lens

INDICATIONS (Uses)

DAILIES TOTAL¹™ for Astigmatism (delefilcon A) soft contact lenses are indicated for the optical correction of refractive anisometropia (myopia and hyperopia) in phakic or aphakic persons with non-diseased eyes with up to 6.00 diopters (D) of astigmatism.

The lenses are to be used for single use, daily disposable wear (less than 24 hours while awake) only. The lenses are not intended to be cleaned or disinfected and should be discarded after a single use.

CONTRAINDICATIONS (Reasons Not to Use)

DO NOT use delefilcon A soft contact lenses when any of the following exists:

- Microbial infection of the eye
- Inflammation or infection of the anterior chamber of the eye
- Any active disease, injury, or abnormality affecting the cornea, conjunctiva, or eyelids that may be exacerbated by contact lens wear
- Inadequate tear film (dry eye) that interferes with contact lens wear
- Reduced corneal sensitivity (corneal hypoesthesia)
- If eyes become red or irritated
- Use of any medication that is contraindicated or interferes with contact lens wear, including certain eye medications
- Any systemic disease which may be exacerbated by or interfere with safe contact lens wear, handling, or care
- Allergic reactions of the ocular surfaces or adnexa that may be caused by or exacerbated by the wearing of contact lenses
- Patient history of recurring eye or eyelid infections, adverse effects associated with contact lens wear, intolerance, or abnormal ocular response to contact lens wear

WARNINGS

Advise patients of the following warnings pertaining to contact lens wear:

- Problems with contact lenses and lens care products could result in serious injury to the eye. It is essential that patients follow their Eye Care Professional's directions and all labeling instructions for proper use of lenses and lens care products. **Eye problems, including corneal ulcers, can develop rapidly and lead to loss of vision.**
- If a patient experiences eye discomfort, foreign body sensation, excessive tearing, vision changes, or redness of the eye, the patient should be instructed to immediately remove lenses and promptly contact his or her Eye Care Professional. It is recommended that contact lens wearers see their Eye Care Professional regularly as directed.
- Studies have shown that contact lens wearers who smoke have a greater risk of suffering ulcerative keratitis than among those who are nonsmokers.^{1,2}
- Daily wear lenses are not indicated for overnight wear, and patients should be instructed not to wear lenses while sleeping. Clinical study results³ have shown that the risk of ulcerative keratitis is greater for daily wear users who wear their

lenses overnight (outside the approved indication) compared to those who do not wear them overnight.

- Non-sterile liquids (i.e., tap water, distilled water, homemade saline solution, or saliva) should not be used as a substitute for any component in the lens care process. The use of tap and distilled water has been associated with *Acanthamoeba keratitis*, a corneal infection that is resistant to treatment and can be fatal.

PRECAUTIONS

To prevent damage to the eyes or to the contact lenses, the following precautions should be taken:

Special Precautions for the Eye Care Professional

The following patients may not be suitable candidates and/or may experience a higher rate of adverse effects associated with contact lens wear:

- Patients with a history of non-compliance with contact lens care and disinfection regimen, wearing restrictions, wearing schedule or follow-up visit schedule.
- Patients who are unable or unwilling to understand or comply with any directions, warnings, precautions, or restrictions. Contributing factors may include but are not limited to age, infirmity, other mental or physical conditions, and adverse working or living conditions.
- Patients with diabetes may have reduced corneal sensitivity. As a result, they are more prone to corneal injury and will not heal as quickly or completely as non-diabetics.

Note regarding lens design and parameters:

Due to the small number of patients enrolled in the clinical investigation of lenses, all refractive powers, design configurations, and lens parameters available in the lens material are not evaluated in significant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, central and peripheral thickness, and optic zone diameter.

The potential impact of these factors on the patient's ocular health should be carefully weighed against the patient's need for refractive correction. Therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully evaluated on initial dispensing and monitored on an ongoing basis by the prescribing Eye Care Professional.

Note the following precautions during initial dispensing and subsequent visits:

- Fluorescein, a yellow dye, should not be used while the lenses are on the patient's eyes. The lenses absorb this dye and become discolored. Whenever fluorescein is used, the eyes should be flushed thoroughly with sterile saline solution that is recommended for in-eye use prior to inserting lenses. Avoid dispensing saline from an aseptically sealed container directly into the eye.
- Instruct the patient to remove the lenses immediately if the eye becomes red or irritated.
- Visual changes or changes in lens tolerance may occur during pregnancy or use of oral contraceptives. Caution patients accordingly.
- Patients who wear contact lenses to correct presbyopia may not achieve the best corrected visual acuity for either far or near vision. Vision requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
- Before leaving the Eye Care Professional's office, patients should be able to promptly remove their lenses or should have someone else available who can remove their lenses for them.

Eye Care Professionals should carefully instruct the patient to take the following care regimen and safety precautions:

Handling Precautions

- Be sure that before leaving the Eye Care Professional's office, the patient is able to promptly remove lenses or have someone else available to remove them.
- Good hygiene habits help promote safe and comfortable lens wear. Always wash, rinse, and dry hands with a lint-free towel before handling lenses.
- Carefully follow the handling, insertion, removal, cleaning, disinfecting, storing, and wearing instructions in the Patient Instruction Booklet for DAILIES TOTAL¹™ for Astigmatism (delefilcon A) Soft Contact Lenses and any additional instructions provided by the Eye Care Professional.
- Note the correct lens power for each eye to prevent getting them mixed up.
- Never use tweezers or other sharp objects such as fingernails to remove lenses from the lens container.
- Always handle lenses carefully. If a lens is dropped, small particles or fibers may adhere to the lens surface, which can irritate the eye. Replace with a sterile new lens.
- Discard any lens that has become dehydrated or damaged. Replace with a sterile new lens.

Lens Wearing Precautions

- Remove the lenses before sleeping. Never exceed the prescribed wearing schedule regardless of how comfortable the lenses feel. Doing so may increase the risk of adverse effects.
- Always keep a supply of replacement lenses on hand or have back-up spectacles available, as lenses should not be reused.
- Do not share lenses with anyone as this may spread microorganisms, which could result in serious eye health problems.
- Lenses should be disposed of each day upon removal from the eye.
- The lens should move freely on the eye at all times. If the lens sticks (stops moving) on the eye, follow the recommended directions in the **CARE FOR A STICKING, TURN, OR OFF-CENTERED LENS** section. If non-movement of the lens continues, consult your Eye Care Professional immediately.

- **REMOVE THE LENS IMMEDIATELY** if your eye becomes red or irritated.
- Promptly remove the lens to avoid serious injury in the event that dust, a foreign body, or other contaminant gets between the lens and the eye.
- Avoid all harmful or irritating vapors and fumes while wearing lenses to reduce the chance of lens contamination or physical trauma to the eye.
- Eye irritation, infection, or lens damage may result if cosmetics, lotion, soap, cream, hair spray, deodorant, aerosol products, or foreign particles come in contact with lenses. If sprays are used, eyes should be kept closed until the spray has settled.
- Consult an Eye Care Professional about wearing lenses during water sports and water related activities. Contact lens exposure to non-sterile water during activities such as swimming, water skiing, and hot tubs may increase the risk of ocular infection including, but not limited to, *Acanthamoeba keratitis*.
- Never allow contact lenses to come into contact with non-sterile liquids (including tap water and saliva) as microbial contamination can occur, which may lead to permanent eye damage.
- Do not use lenses beyond the expiration date.

Solution Precautions

- Do not use saliva or any liquid other than the recommended solution for lubricating or rewetting drops with the lenses.

Other Topics to Discuss with Patients

- Periodic eye examinations are extremely important for contact lens wearers. Schedule and conduct appropriate follow-up examinations to determine ocular response. Alcon recommends that patients see their Eye Care Professional at least once each year or as recommended by the Eye Care Professional.
- Certain medications may cause dryness of the eye, increased lens awareness, lens intolerance, blurred vision, or visual changes. These include, but are not limited to, antihistamines, decongestants, diuretics, muscle relaxants, tranquilizers, and those for motion sickness. Caution patients using these medications accordingly and prescribe proper remedial measures.
- Visual changes or changes in lens tolerance may occur during pregnancy or use of oral contraceptives. Caution patients accordingly.

It is strongly recommended that patients be provided with a copy of the DAILES TOTAL 1™ for Astigmatism (disflicon A) soft contact lens Patient Instruction Booklet available from Alcon. It is important that patients understand its contents prior to dispensing the lenses.

Who Should Know the Patient is Wearing Contact Lenses

- Instruct patients to inform their employers that they are wearing contact lenses. Some jobs may require the use of eye protection equipment or may prohibit the wearing of contact lenses.
- Instruct the patients to inform their health care professionals that they are wearing contact lenses, as certain medications may interfere with contact lens wear.

WATER ACTIVITIES

Do not expose contact lenses to water while wearing them.

Warning:

Water can harbor microorganisms that can lead to severe infection, vision loss or blindness. If lenses have been submerged in water when showering or swimming, discard them and replace with a new pair. Ask the Eye Care Professional for recommendations about wearing lenses during any activity involving water.

ADVERSE EFFECTS (Possible Problems)

Patients should be instructed to check their eyes regularly to make sure they look well, feel comfortable, and vision is clear.

Potentially serious complications are usually accompanied by one or more of the following signs and symptoms:

- Moderate to severe eye pain not relieved by removing the lens
- Feeling of something in the eye (foreign body sensation)
- Excessive watering or other eye secretions, including mucopurulent discharge
- Redness of the eyes
- Sensitivity to light (photophobia)
- Burning, stinging, itching or other pain associated with the eyes
- Comfort is less compared to when the lens was first placed on eye
- Reduced sharpness of vision (poor visual acuity)
- Blurred vision, rainbows, or halos around objects
- Feeling of dryness

These symptoms, if ignored, may lead to more serious complications.

WHAT TO DO IF A PROBLEM OCCURS

If any of the above signs or symptoms occur:

- **IMMEDIATELY REMOVE THE LENSES.**
- If the discomfort or problem stops, discard the lens and replace it with a new one.
- If the discomfort or problem continues after removing the lens(es) or upon insertion of a new lens, **IMMEDIATELY** remove the lens(es) and contact an Eye Care Professional for identification of the problem and prompt treatment to avoid serious eye damage.
- Eye Care Professionals should inform the patient that a serious condition such as corneal ulcer, ulcerative keratitis, infection, corneal vascularization, or iritis may be present. These conditions may progress rapidly and may lead to permanent loss of vision. Less serious reactions such as abrasions, infiltrates, and bacterial conjunctivitis must be managed and treated properly to avoid more serious complications.
- Additionally, contact lens wear may be associated with ocular changes that require consideration of discontinuation or restriction of wear. These include, but are not limited to, local or generalized corneal edema, epithelial microcysts, epithelial staining, infiltrates, neovascularization, endothelial polymegathism, tarsal papillary changes, conjunctival injection, or iritis.

CARE FOR A STICKING, TORN, DECENTERED, OR DRY LENS

Patients should be informed that it may be possible to resolve less serious problems associated with contact lens wear by following the directions below. However, if following these directions does not resolve the problem, patients should consult their Eye Care Professional immediately to avoid injury to the eye.

- **The lens should move freely on the eye at all times.** If the lens sticks (stops moving) or begins to dry on the eye, apply several drops of a recommended lubricating solution (used in accordance with package labeling). Wait until the

lens begins to move freely on the eye before attempting to remove it. It is important that you wash and dry your hands thoroughly before removing the lens. If the lens continues to stick, **IMMEDIATELY** contact your Eye Care Professional.

- **If a lens tears in your eye,** remove the pieces carefully by pinching them as you would for normal lens removal. If the lens pieces do not seem to remove easily, do not pinch the eye tissue. Rinse with saline. If this does not help, contact the Eye Care Professional for assistance.
- **If a lens decenters on the eye,** it may be possible to re-center it by:
 - Closing your eyelids and gently massaging the lens into place, or
 - Looking in the direction of the lens and blinking gently, or
 - Gently pushing the off-centered lens onto the cornea with light finger pressure on the edge of the upper or lower eyelid.
- **Occasional dryness** may be relieved by blinking fully several times or by the use of contact lens rewetting drops that are approved for use with soft contact lenses. If dryness persists, consult your Eye Care Professional.

EMERGENCIES

If chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes:

- Flush eyes immediately with fresh saline solution or tap water.
- Remove and discard lenses and immediately contact the Eye Care Professional or visit a hospital emergency room without delay.

ADVERSE EFFECT REPORTING

If a patient experiences any serious adverse effects associated with the use of Disflicon A contact lenses, please notify: **Alcon Medical Affairs in the USA at 1-800-787-9780.**

FITTING GUIDE AND PATIENT BOOKLET

Conventional methods of fitting contact lenses apply to DAILES TOTAL 1™ for Astigmatism (disflicon A) contact lenses. For a detailed description of the fitting techniques, refer to the DAILES TOTAL 1™ for Astigmatism (disflicon A) soft contact lens Professional Fitting and Information Guide for more information. Both the Professional Fitting and Information Guide and a Patient Instruction Booklet are available free of charge from:

Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, TX 76134-2099, USA
or by calling Alcon Customer Service in the USA at:
1-800-241-6399

LENS WEAR AND REPLACEMENT SCHEDULE

Daily Wear (less than 24 hours, while awake)

- Normal daily wear of lenses assumes a minimum of 6 hours of non-lens wear per 24-hour period; however, optimum individual wearing schedules will vary.
- The maximum daily wearing time should be determined by the Eye Care Professional based upon the patient's physiological eye condition because individual responses to contact lenses vary.
- Daily wear patients may initially over-wear the lenses. Avoid this tendency by stressing the importance of adhering to a proper initial wearing schedule. For patients who are new to daily wear, gradually increasing scheduled wearing time may allow ocular tissues to more easily adapt to contact lens wear.

Lens Replacement

• Disflicon A contact lenses are intended to be worn once (daily disposable wear) and then discarded at the end of each wearing period. The patient should be instructed to start the next wearing period with a fresh new lens.

LENS HANDLING INSTRUCTIONS

- Always wash and rinse hands thoroughly and dry completely with a clean, lint-free towel before handling contact lenses.
- Note the correct lens power for each eye to avoid getting them mixed up.
- Do not use if blister package is damaged or not sealed completely. This may result in product contamination, which can lead to a serious eye infection.
- Shake the blister pack (containing a fresh new lens) gently prior to opening.
- Remove the lens from the blister pack by carefully pouring it into the palm of the hand.
- Ensure that the lens is right side out.
- Inspect the lenses prior to insertion. Do not insert damaged or unclean lenses.

Lens Insertion Instructions

- Wash and rinse hands thoroughly and dry completely with a clean, lint-free towel.
- Place a lens on the tip of your clean and dry right or left index finger. Place the middle finger of the same hand close to lower eyelashes and pull down the lower eyelid.
- Use the fingers of the other hand to lift the upper eyelid.
- Place the lens directly on the eye (cornea) and gently roll finger away from the lens.
- Look down and slowly release the lower lid.
- Look straight ahead and slowly release the upper lid.
- Blink gently.

Lens Removal Instructions

- Wash and rinse hands thoroughly, and dry completely with a clean, lint-free towel.
- Blink fully several times.
- While looking up, use the tip of the finger to slide the lens down onto the white part of the eye.
- Remove the lens by pinching gently between thumb and forefinger. Do not pinch the eye tissue.
- If the lens is difficult to grasp, dry fingers once more and try again. Do not use rewetting drops in this instance.
- Never use tweezers or other sharp objects such as fingernails to remove lenses from your eyes.

LENS CARE DIRECTIONS

- To help avoid serious eye injury from contamination, the Eye Care Professional should review the following instructions with the patient:
- Cleaning and disinfection of daily disposable lenses is not recommended. The

patient should be reminded to have replacement lenses or back-up spectacles available at all times.

- Do not use saline, tap water, homemade saline solution, distilled water or anything other than the recommended rewetting drops or lubricants indicated for use with soft lenses.

DISPOSAL AND RECYCLING

Dispose of contact lenses and the blister pack (lidding in the waste bin, not down the toilet or sink. The carton packaging and the polypropylene (PP) plastic shell of the blister pack should be placed in the waste bin or recycled according to local waste management guidance.

IN OFFICE USE OF TRIAL LENSES

Eye Care Professionals should educate contact lens technicians concerning proper use of trial lenses. Each contact lens is shipped sterile in a blister pack containing phosphate buffered saline solution. Hands should be thoroughly washed, rinsed, and dried with a lint-free towel prior to handling a lens. In order to ensure sterility, the blister pack should not be opened until immediately prior to use. For fitting and diagnostic purposes, the lenses should be disposed of after a single use and not be re-used from patient to patient.

HOW SUPPLIED

Each lens is packaged in a foil-sealed plastic blister pack containing phosphate buffered saline solution with approximately 0.3% of polymeric wetting agents consisting of copolymers of polyamidoamine and polyacrylamide-acrylic acid and is steam sterilized. The package is marked with the base curve, diameter, dioptric power, cylinder axis and power (where applicable), ADD power (where applicable), manufacturing lot number, date of manufacture, and expiration date. Lenses are supplied in cartons containing up to 90 individually sealed contact lenses.

The following may appear on labels or cartons:

Symbol / Abbreviation	Description
BC	Base Curve
DIA	Diameter
PWR	Power
D	Diopter
L	Left
R	Right
CYL AXIS	Cylinder power and axis
UV	Ultra-violet
UVA	Ultra-violet A
UVB	Ultra-violet B
UV VIS	Ultra-violet and Visible
HEVL	High Energy Visible Light (blue light)
	Packaging waste disposal
	Do not re-use
	Batch code
	Use-by date (expiry date)
	Single sterile barrier system
	Sterilized using steam
CE	European conformity mark
	English (example of two letter code for the language)
	Caution
	Consult instructions for use
	Do not use if blister package is damaged
	DO NOT DISPOSE LENSES IN TOILET OR SINK
	Manufacturer
	Date of manufacture
	Medical device
	Authorized representative in the European Community
	CAUTION: Federal (United States) law restricts this device to use by or on the order of a licensed eye care professional

Manufacturer:
Alcon Laboratories, Inc.
6201 South Freeway
Fort Worth, TX 76134-2099, USA

Date: August 2021

U.S. Pat.: www.alconcontacts.com

¹ Check for actual product availability which may change over time.
² Cutler GR, Chalmers RL, Roseman M. The Clinical Presentation, Prevalence, and Risk Factors of Focal Corneal Infiltrates in Soft Contact Lens Wearers. *The CLAO Journal*. Jan 1996; 22 (1): 30-37.
³ Schein OD, Glynn RJ, Poggio EC, Seddon JM, Kenyon KR. The Relative Risk of Ulcerative Keratitis Among Users of Daily-Wear and Extended-Wear Soft Contact Lenses. *The New England Journal of Medicine*. 1999; 321(12): 773-783.

Alcon

© 2021 Alcon Inc.

W9004/09251-002/1

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX D: [REDACTED] [REDACTED]

- [REDACTED] LENS FITTING CHARACTERISTICS
- [REDACTED] DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
- [REDACTED] TORIC FIT EVALUATION
- [REDACTED] PATIENT REPORTED OUTCOMES

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

LENS FITTING CHARACTERISTICS

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

[REDACTED] DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

TORIC FIT EVALUATION

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

[REDACTED] PATIENT REPORTED OUTCOMES

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX E: [REDACTED]

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX F: [REDACTED]

the 1990s, the number of people in the UK who are aged 65 and over has increased from 10.5 million to 12.5 million, and the number of people aged 75 and over from 4.5 million to 6.5 million (Office for National Statistics 2000). The number of people aged 65 and over is projected to increase to 15.5 million by 2020, and the number of people aged 75 and over to 8.5 million (Office for National Statistics 2000).

There is a growing awareness of the need to address the needs of older people in the UK. The Department of Health (2000) has published a strategy for older people, which sets out a vision for a society in which older people are able to live well, and to contribute to society. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes. The strategy is based on three main principles: (1) older people should be able to live well, (2) older people should be able to contribute to society, and (3) older people should be able to live in their own homes.

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

**APPENDIX G: WORKAID FOR AUTOMATED TRACKING OF THE LENS ORIENTATION
MARKER ON SOFT TORIC CONTACT LENSES**

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

APPENDIX H: [REDACTED] GUIDELINES FOR COVID-19 RISK MITIGATION

1.0 PURPOSE

The purpose of this document is to provide guidelines for clinical study sites participating in Johnson & Johnson Vision Care (JJVC) clinical studies during the COVID-19 pandemic.

2.0 SCOPE

This document provides guidelines for Johnson & Johnson Vision Care (JJVC) to address the potential risks from COVID-19 to study subjects, investigators, study site staff, and monitors at study sites. The guidance provided in this document is in effect from the date of approval through the date of retirement of this Work Instruction. This Work Instruction will be reviewed and updated as needed.

As of May 2023, the World Health Organization (WHO) declared an end to COVID-19 as a public health emergency. The Centers for Disease Control and Prevention (CDC) also updated its Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic in May 2023. References for regulations and industry guidelines can be found in the Resource Links section below.

Evaluation of sites outside of the United States (OUS) will be performed on a country-by-country basis subject to local health authority guidance. If the OUS site resides in a country requiring greater than standard of care practices to prevent the spread of COVID-19 in an optometric setting, this guidance can be applied for the JJVC clinical study at that site.

This work instruction can also be utilized for sites within the United States if changes in government recommendations occur or based on the preference of the clinical site, or investigator.

3.0 DEFINITIONS

American Academy of Optometry (AAO): The American Academy of Optometry is an organization of optometrists based in Orlando, Florida. Its goal is to maintain and enhance excellence in optometric practice, by both promoting research and the dissemination of knowledge. The AAO holds an annual meeting, publishes a monthly scientific journal, gives credentials to optometrists through the fellowship process and publishes position statements.

American Optometric Association (AOA): The American Optometric Association, founded in 1898, is the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take a leading role in patient care with respect to eye and vision care, as well as general health and well-being. As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, diagnose, treat and manage ocular disorders, diseases and injuries and systemic diseases that manifest in the eye. The American Optometric Association is a federation of state, student, and armed forces optometric associations. Through these affiliations, the AOA serves members consisting of optometrists, students of optometry, paraoptometric assistants and technicians. The AOA and its affiliates work to provide the public with quality vision and eye care.

Centers for Disease Control and Prevention (CDC): The Centers for Disease Control and Prevention is a national public health institute in the United States. It is a United States federal agency, under the Department of Health and Human Services, and is headquartered in Atlanta, Georgia.

COVID-19: Current outbreak of respiratory disease caused by a novel coronavirus. The virus has been named "SARS-CoV-2" and the disease it causes has been named "Coronavirus Disease 2019" (COVID-19).

Clinical Study: Voluntary research studies conducted in people and designed to answer specific questions about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing treatments. May also be called clinical trials, studies, research, trials, or protocols.

Clinical Study Site: Location where a clinical study is conducted, such as a doctor's office, university, or laboratory. Clinical studies are conducted by Investigators who are individual(s) responsible for the conduct of the clinical study at a study site. If a study is conducted by a team of individuals, the Investigator is the responsible leader of the team and may be called the Principal Investigator.

Clinical Operations Manager (COM): The Johnson & Johnson Vision Care (JJVC) individual responsible for the overall management of a clinical trial.

Monitor: An individual designated to oversee the progress of a clinical study and ensure that it is conducted, recorded, and reported in accordance with the protocol, Standard Operating Procedures (SOPs), Good Clinical Practice (GCP), and applicable regulatory requirements.

Medical Safety Officer (MSO): Physician who has primary accountability in their product portfolio for product health and safety, and who serves as an independent medical voice for patient safety.

Safety Management Team (SMT): A cross-functional, collaborative team responsible for review, assessment and evaluation of medical safety data arising from any source throughout the product life cycle.

4.0 GUIDANCE FOR STUDY DOCUMENTS

In alignment with recent health authority guidance, JJVC is providing recommendations for study-related management in the event of disruption to the conduct of the clinical study. This guidance does not supersede any local or government requirements or the clinical judgement of the investigator to protect the health, safety and well-being of participants and site staff. If, at any time, a participant's safety is considered to be at risk, study intervention will be discontinued, and study follow-up will be conducted as outlined in the protocol.

During the COVID-19 pandemic, the additional risks listed below need to be considered for study participants and study personnel:

4.1 Additional Risks Related to the COVID-19 Pandemic:

- The possible transmission of the Coronavirus infection and consequent complications, beyond the risk of adverse events due to the investigational device and/or procedures.
- The risk may be higher in an optometric clinical study because of the close contact the subject will have with health care professionals during the procedures and assessments (since the investigator must make the measurements close to the subject's face) and, in addition the need for multiple follow-up visits/exams which may expose the subject to other patients and/or healthcare professionals who might be transmitting the virus, even if they do not have symptoms.
- Potential disruptions to the study may be necessary due to current or future pandemic-related emergency restrictions, which may lead to delays in scheduled follow-up visits.
- Subjects experiencing an adverse event related to contact lens wear may receive delayed treatment due to COVID-19 restrictions. In this event, all assessments that can be conducted virtually will be completed by the investigator to determine the best course of treatment for the subject, including an unscheduled visit, up to discontinuation from the study, as appropriate.

If a study subject is found to have contracted COVID-19 during participation in a study, he/she will be discontinued from the study and followed until COVID-19 Adverse Event (AE) resolution.

To help minimize the above potential risks, JJVC recommend reviewing/complying with local, state, and governmental guidance for COVID-19 risks.

JJVC will provide the following study specific documents with language pertaining to COVID-19 risks:

4.1.1 Informed Consent:

Will include information concerning the study-associated risks related to the COVID-19 pandemic in bold font and/or boxed on the first page of the Informed Consent document:

STUDY ASSOCIATED RISKS RELATED TO COVID-19 (CORONAVIRUS) PANDEMIC

It is important to note that this study will be conducted, at least in part, during the COVID-19 pandemic. As such, additional risks associated with the infection with COVID-19 exist for you. This is particularly important for this study due, in part, to the closeness of the doctor during the study examinations.

The potential effects of the disease are not fully known, at this time, and may include long-term serious health consequences. In severe cases, this may result in hospitalization and/or death. Based on current knowledge from the Centers for Disease Control and Prevention (CDC), those at high-risk for severe illness from COVID-19 include older adults and people with underlying medical conditions.

During this study, all appropriate measures will be taken to minimize risks including the use of personal protective equipment such as masks and gloves, as well as proper sanitization. This is in conformance to guidance from the CDC, local health departments, and the state and county in which the study doctor's office is located. However, these measures may not completely eliminate the risks associated with contracting COVID-19.

If you are found to have contracted COVID-19 or feel ill with flu-like symptoms during participation in the study, you will not be permitted to continue in-office study follow-up visits, but you will receive instructions and your condition will be monitored by the doctor and/or study staff.

4.1.2 COVID-19 Risk Control Checklist (Attachment-B):

Will include COVID-19 risk control methods that are required by a site to conduct JJVC clinical studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Principal Investigator will review/sign the study specific checklist prior to the Site Initiation Meeting.

4.1.3 Protocol Compliance Investigator(s) Signature Page:

Will include a statement indicating that the Principal Investigator (PI) agrees to conduct the study in compliance with all local, state, and governmental guidance's for COVID-19 risk mitigation.

I have read the suggested guidance provided by JJVC pertaining to the COVID-19 risk mitigation, (COVID-19 Work Instruction in the Appendix of this protocol). I agree to conduct this study in compliance with local, state, governmental guidance for COVID-19 risks.

4.1.4 Study Site Initiation Training Slides:

Will include suggestions to help mitigate potential transmission of COVID-19. Suggestions may include maintaining social distancing in the clinical site by staggered scheduling of study patients, wearing proper PPEs, frequent disinfection, and installing shields on the slit lamp and other applicable equipment.

5.0 GUIDANCE FOR REMOTE SUBJECT VISITS

Potential disruptions to the study may be necessary due to current or future pandemic-related emergency restrictions. Possible disruption of the study as a result of COVID-19 control measures may lead to delays in scheduled follow-up visits.

Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID-19 control measures or due to the subject's concerns or fears about COVID-19 risk. When appropriate, the remote assessment will be conducted to the extent possible. Discussions with the subject during remote assessments may include:

Procedure	Details
Subject Reported Ocular Symptoms	Subjects will respond to a verbal open-ended symptoms questionnaire regarding the test article when applicable and feasible.
Change of Medical History (Adverse Events) and Concomitant Medications / Therapies Review	Record any adverse events or medical history changes from the previous study visit with the subject/parents. Review the subject's concomitant medications/therapies and record any changes from the previous study visit.
Wearing Time and Compliance	Record the average wearing time (including number of hours per day during weekdays and weekends, and number of days per week). Confirm compliance with the prescribed wear schedule. Record and discuss the lens wear compliance based on the subject's self-report. For example, the subjects will be asked the time of the day the subject typically puts on the study lenses in the morning and takes off in the evening, the number of days per week lenses were worn, and the number of consecutive days the subject didn't wear the study lenses, etc.

The discussion with the subject will be documented in EDC under Tele-Visit and a minor protocol deviation will be noted. If during the telephone consultation, a subject states he/she wishes to discontinue participating in the study, instruct the subject to stop wearing the study lenses and schedule the subject to return to the clinic for a Final Evaluation at the at earliest possible time. Subjects should return all unused lenses to the clinic at the last visit.

Changes in study visit schedules, missed visits, or participant discontinuations may lead to missing data, including data related to protocol-specified procedures. Case report forms should capture specific information regarding the basis of missing data, including the relationship to the COVID-19 pandemic.

6.0 STUDY CONDUCT DURING PANDEMIC

It is recognized that the Coronavirus Disease 2019 (COVID-19) pandemic may have an impact on the conduct of this clinical study due to, for example, self-isolation/quarantine by participants and study-site personnel; travel restrictions/limited access to public places, including Optometry Clinics; and changes in clinic procedures required to address the COVID-19 challenge.

Every effort should be made to adhere to protocol-specified assessments for study participants, including follow-up. However, if scheduled visits cannot be conducted in person at the study site it is suggested that assessments be performed to the extent possible remotely/virtually or delayed until such time that on-site

visits can be resumed in order to continue participant monitoring in accordance with the protocol where possible. At each contact, participants will be interviewed to collect safety data. Key efficacy endpoint assessments should be performed if required and as feasible.

Modifications to protocol-required assessments may be permitted via COVID-19 Appendix after consultation with the participant, investigator, and the sponsor. Missed assessments/visits will be captured in the clinical trial management system for protocol deviations. Interruptions of test article wear or discontinuations of study interventions and withdrawal from the study should be documented with the prefix "COVID-19-related" in the case report form (CRF).

The sponsor will continue to monitor the conduct and progress of the clinical study, and any changes will be communicated to the sites and to the health authorities according to local guidance.

If a participant has tested positive for COVID-19, the investigator should contact the sponsor's responsible monitor to discuss initial plans for study intervention and follow-up. The monitor will notify the Safety Management Team of any subject(s) that have reported "COVID-19", "Asymptomatic COVID-19", "COVID-19 Exposure", or "Suspected COVID-19" adverse events within 24 hours of the notification.

Modifications made to the study conduct as a result of the COVID-19 pandemic will be summarized in the clinical study report.

6.1 Monitoring Visits

When on-site monitoring by the sponsor is not feasible, the sponsor's site monitor will contact the study site to schedule remote visits. In such cases, on-site monitoring visits will resume when feasible, with increased frequency to address the source data verification backlog.

Even with staffing limitations during this COVID-19 pandemic, all routine operations related to clinical trials should be well-documented and archived as part of standard process. When conditions permit, all parties involved in this clinical trial should communicate relevant information in a timely manner so that all relevant parties remain sufficiently informed.

6.1.1 Study Site Initiation:

During the period that this Work Instruction is in effect, Site Initiation Meetings and training of study site staff may be conducted remotely. The JJVC study team will conduct training via Skype, Zoom, Microsoft Teams or similar software as well as utilize online training materials, as applicable. Study site training will be documented utilizing Site Initiation Report [REDACTED] per Study Site Initiation [REDACTED]

On-site visits may be considered when, for example, hands-on training or evaluation of site facilities is required. While on site, the Clinical Research Associate (CRA) will follow all local, state, and governmental policies for COVID-19 Risk Mitigation, including social distancing, wearing of PPE, etc. as applicable for the location of the study site.

6.1.2 Interim Monitoring Visits (if applicable):

During the period that this Work Instruction is in effect, Interim Monitoring On-site visits may be kept to a minimum and include only those tasks that the CRA cannot perform remotely (e.g., source document verification, test article reconciliation, etc.).

To ensure data integrity during the conduct of all JJVC studies, clinical study teams will follow the study specific Clinical Monitoring Plan [REDACTED]

While on site, the CRA will follow all local, state, and governmental policies for COVID-19 Risk Mitigation, including social distancing, wearing of PPE, etc. as applicable for the location of the study site.

6.1.3 Study Site Closure:

During the period that this Work Instruction is in effect, the duration of the Study Site Closure Visit may be limited to tasks that the CRA cannot perform remotely (e.g., source document verification, test article final reconciliation and return, etc.).

Title:	Guidelines for COVID-19 Risk Mitigation	
Document Type:		
Document Number:		Revision Number: 6

Attachment A: Study Site Correspondence

MONTH DD, YYYY

Re: COVID-19 Mitigation Plan, <<[REDACTED]/protocol title>>

Dear <<Principal Investigator>> and Study Team,

Coronavirus (COVID-19) has impacted several communities and business activities over the past several years. While we work toward the successful conduct of clinical studies, our commitment continues to be the safety of patients, healthcare professionals, and to our communities.

Therefore, we would like to share the following revisions/additions related to the above referenced Johnson & Johnson Vision Care company sponsored clinical trial(s) you are currently working on or considering participation within.

Protocol:

- Guidelines for COVID-19 Risk Mitigation provided in the Appendix section.

Protocol Signature Page:

- Will include a statement indicating the Principal Investigator agrees to conduct the study in compliance with all local, state, and governmental guidelines for COVID-19 risk mitigation.

Informed Consent:

- Will include information concerning the study-associated risks related to the COVID-19 pandemic in bold font and/or boxed on the first page of the Informed consent document.

COVID-19 Risk Control Checklist for Clinical Studies:

- Will include COVID-19 risk control measures that are required to ensure the safety and health of subjects, site staff and monitors during the pandemic.

We want to encourage the need for open lines of communication about potential challenges you may foresee as the result of the current COVID-19 situation. Therefore, we encourage you to regularly connect with your respective Johnson & Johnson clinical study team (Clinical Research Associate (CRA), Lead CRA or Study Managers).

Thank you for your continued engagement, collaboration, and dedication to your study subjects during this challenging time.

Please file this letter in your site file study correspondence.

Attachment B: COVID-19 Risk Control Checklist

Study Number

Site Number

Principal Investigator (PI) Name

The following risk control operational measures are to be implemented in order to mitigate the risks of contracting COVID-19 illness by patients and/or staff participating in Johnson & Johnson Vision Care (JJVC) clinical studies. Any local regulations, industry guidelines and COVID-19 policy at the institution/clinic should be followed in addition to this checklist.

PI Initials	General Site Safety Planning Measures
	Signage within site describing Risk Control methods
	Social Distancing practices throughout site (waiting rooms, lobby, exam rooms, etc.)
	Training on patient flow and physical distancing in waiting room
	Establish longer time frame between patient appointments to reduce persons in the site
	Staff should receive job-specific training on PPE and demonstrate competency with selection and proper use of PPE and wear at all times during interactions with subjects (e.g., putting on and removing without self-contamination)

PI Initials	Site Staff Daily Safety Measures
	As part of routine practice, site staff should regularly monitor themselves for fever and symptoms of COVID-19, including temperature checks
	Any staff member (including non-study clinic staff and Investigators) showing signs of being sick or testing positive for COVID-19 must not be permitted to work on activity that may expose study related staff and subject and the Sponsor shall be informed NOTE: Inform JJVC in 24 hours of any COVID-19 cases and all potential exposure during the clinical study.
	Ensure that all staff wear a mask Gloves should be worn if there is physical direct patient contact and changed between each patient
	Have staff thoroughly wash hands for at least 20 seconds or use an alcohol-based hand sanitizer when they arrive, before and after each patient, before eating and after using the bathroom.
	Cleaning and disinfection procedures for exam rooms and instruments or equipment between patients with gloves.
	Cleaning and disinfection procedures for commonly touched surfaces (doors, chairs, computers, phones, etc.) with gloves.

PI Initials	Before a Patient or Study Visit:
	Patients should be asked prior to entering the site about fever and respiratory illness and whether they or a family member have had contact with another person with confirmed COVID-19 in the past 14 days. Patients exhibiting signs of being sick should be rescheduled when their symptoms resolve. Patients who have had close contact with someone with confirmed or suspected COVID-19 infection should contact the site to report exposure.

Title: Guidelines for COVID-19 Risk Mitigation

Document Type:

Document Number:

Revision Number: 6

PI Initials	Patients Entering the site:
	All patients and companions must wear cloth or disposable mask at all times in the site
	Maintain social distancing. Waiting rooms or lobbies should be as empty as possible. Advise seated patients to remain at least 6 feet from one another.
	Communal objects in (e.g. toys, reading materials, etc.) should be removed or cleaned regularly.

I certify that I have read and agree to implement all the listed COVID-19 Risk Control Measures required for the conduct of Johnson & Johnson Vision Care studies. I agree to the disclosure of potential risks due to COVID-19. If any of the risk mitigation precautions change during the course of the study, I will contact Johnson & Johnson. I understand the possible risks of COVID-19 transmission if our facility's measures are not aligned with the above.

Principal Investigator Signature and Date

RESOURCE LINKS

- WHO chief declares end to COVID-19 as a global health emergency:
<https://news.un.org/en/story/2023/05/1136367>

US Resource Links

- CDC Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic <https://www.cdc.gov/coronavirus/2019-ncov/hcp/infection-control-recommendations.html>
- OSHA Protecting Workers: Guidance on Mitigating and Preventing the Spread of COVID-19 in the Workplace: <https://www.osha.gov/coronavirus/safework>
- CDC Training for Healthcare Professionals : <https://www.cdc.gov/coronavirus/2019-ncov/hcp/training.html>
- I&R Training ACUVUE® LensAssist: <https://www.acuvue.com/lensassist>
- American Optometric Association COVID-19 latest updates: <https://www.aoa.org/covid-19/covid-19-latest-updates>

OUS Resource Links

- Hong Kong
 - Updates on local regulations: <https://www.coronavirus.gov.hk/eng/index.html>
- England
 - NHS Updates and Guidance for Optical Settings: <https://www.england.nhs.uk/coronavirus/publication/updates-and-guidance-for-optical-settings/>
- United Kingdom
 - The College of Optometrists primary eye care COVID-19 guidance: <https://www.college-optometrists.org/the-college/media-hub/news-listing/coronavirus-covid-19-guidance-for-optometrists.html>
 - NHS advice about COVID-19, including symptoms, testing, vaccination and staying at home: <https://www.nhs.uk/conditions/coronavirus-covid-19/>
- Canada
 - COVID-19 for health professionals: Infection prevention and control: <https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/infection-prevention-control.html>
- Australia
 - Optometry Australia: Infection control guidelines and advice [Infection control guidelines and advice - Optometry Australia](#)

Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.

PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE

Protocol Number and Title: CR-6576 Evaluation of Lens Rotation in Habitual Wearers of Toric, Soft Contact Lenses

Version and Date: 1.0 03 October 2024

I have read and understand the protocol specified above and agree on its content.

I agree to conduct this study according to ISO 14155:2020¹, Declaration of Helsinki², United States (US) Code of Federal Regulations (CFR)³, and International Council for Harmonization Good Clinical Practice E6(R2) (ICH GCP)⁴ and the pertinent individual country laws/regulations and to comply with its obligations, subject to ethical and safety considerations. I, as the Principal Investigator, am responsible for ensuring that all clinical site personnel, including Sub-Investigators, adhere to all regulations and GCP guidelines regarding clinical trials during and after study completion.

I will assure that no deviation from or changes to the protocol will take place without prior agreement from the Sponsor and documented approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate hazard(s) to the trial subjects.

All clinical site personnel involved in the conduct of this study will have completed Human Subjects Protection Training before participating in the study.

I agree to ensure that all clinical site personnel involved in the conduct of this study are informed about their obligations in meeting the above commitments.

I shall not disclose the information contained in this protocol or any results obtained from this study without written authorization.

I have read the suggested guidance provided by JJVCI pertaining to the COVID-19 risk mitigation, (COVID-19 Work Instruction in the Appendix H of this protocol). I agree to conduct this study in compliance with local, state, governmental guidance for COVID-19 risks.

Principal
Investigator:

Signature

Date

Name and Professional Position (Printed)

Institution/Site:

Institution/Site Name

Institution/Site Address